m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation

m6A Modification:
Crosstalk ID	M6ACROT05032				[1]
Non-coding RNA miR-33a METTL3 lncRNA miRNA circRNA Direct Inhibition m⁶A modification EGFR EGFR METTL3 Methylation : m⁶A sites
m6A Regulator	Methyltransferase-like 3 (METTL3)			WRITER	Regulator Info
m6A Target	Epidermal growth factor receptor (EGFR)				Targert Gene
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type	Non-coding RNA (ncRNA)
Epigenetic Regulator	hsa-miR-33a			microRNA	View Details
Regulated Target	Methyltransferase-like protein 3 (METTL3)				View Details
Crosstalk Relationship	ncRNA → m6A			Inhibition
Crosstalk Mechanism	ncRNAs directly impacts m6A modification through modulating the expression level of m6A regulator
Crosstalk Summary	hsa-miR-33a suppresses proliferation of NSCLC cells via targeting METTL3 mRNA.miR-33a was able to depress the expression of Epidermal growth factor receptor (EGFR), TAZ, MAPKAPK2 and DNMT3A at the level of protein
Responsed Disease	Non-small cell lung cancer		ICD-11: 2C25.Y		Disease Info
Cell Process	RNA stability
Cell Process	RNA degradation (hsa03018)
In-vitro Model	A-549	Lung adenocarcinoma	Homo sapiens		CVCL_0023
In-vitro Model	NCI-H460	Lung large cell carcinoma	Homo sapiens		CVCL_0459

Full List of Potential Compound(s) Related to This m6A-centered Crosstalk

Epidermal growth factor receptor (EGFR)		222 Compound(s) Regulating the Target	Click to Show/Hide the Full List
Compound Name	Necitumumab		Approved	[2]
Synonyms	LY3012211 Click to Show/Hide
MOA	Modulator
External Link	TTD: D03WPP
Compound Name	HEGF		Approved	[3]
MOA	Activator
External Link	TTD: D05GGP
Compound Name	Erlotinib		Approved	[4]
Synonyms	Erlotinin; Tarceva; Erlotinib Base; OSI 744; R 1415; CP 358,774; CP-358774; Erlotinib(Tarceva); Tarceva (TN); CP-358,774; Erlotinib, OS-774; N-(3-ethynylphenyl)[6,7-bis(2-methoxyethoxy)quinazolin-4-yl]amine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine; N-(3-Ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine; [6,7-BIS(2-METHOXY-ETHOXY)QUINAZOLINE-4-YL]-(3-ETHYNYLPHENYL)AMINE; [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amine; 4-[(3-Ethynylphenyl)amino]-6,7-bis(2-methoxyethoxy)quinazoline Click to Show/Hide
MOA	Inhibitor
Activity	Ki = 0.1 nM
External Link	CID: 176870 TTD: D07POC DrugBank: DB00530
Compound Name	Gefitinib		Approved	[5]
Synonyms	Gefitini; IRE; Iressa; Irressat; Gefitinib [USAN]; ZD 1839; ZD1839; Iressa (TN); Iressa(TM); ZD-1839; CU-00000000396-1; Gefitinib,Iressa, ZD1839; Gefitinib (JAN/USAN/INN); ZD-1839, Iressa, Gefitinib; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamide; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 0.1 nM
External Link	CID: 123631 TTD: D09XZB DrugBank: DB00317
Compound Name	Panitumumab		Approved	[6]
Synonyms	Vectibix; Panitumumab (genetical recombination); Vectibix (TN); Panitumumab (USAN/INN); Panitumumab (genetical recombination) (JAN); Panitumumab (EGFR mAb inhibitor) Click to Show/Hide
MOA	Suppressor
External Link	TTD: D0HU9H
Compound Name	Cetuximab		Approved	[7]
Synonyms	Erbitux; Cetuximab (genetical recombination); Erbitux (TN); Cetuximab (USAN/INN); Cetuximab (genetical recombination) (JAN); novel EGFR mAb inhibitors Click to Show/Hide
External Link	TTD: D0N5OV
Compound Name	BIBW 2992		Approved	[8]
Synonyms	Afatinib; Tomtovok; Tovok; BIBW-2992; Tovok (TN); Tovok, BIBW2992; (2E)-N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[(3S)-tetrahydrofuran-3-yloxy]quinazolin-6-yl}-4-(dimethylamino)but-2-enamide; EGFR inhibitor 2nd gens Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 0.19 nM
External Link	CID: 10184653 TTD: D05UFG DrugBank: DB08916
Compound Name	Nitroglycerin		Approved	[3]
Synonyms	Glyceryl trinitrate; Trinitroglycerin; Nitroglycerol; Nitrostat; Nitroglycerine; Nitro-dur; Minitran; Trinitroglycerol; 55-63-0; Nitroderm; Nitroglyn; Nitrospan; Nitronet; Tridil; Glycerol trinitrate; Transderm-nitro; Transderm Nitro; Epinitril; Susadrin; Perlinganit; Nitrolingual; Nitrolan; Sustonit; Nitrocine; Trinitrin; Natispray; Lenitral; Nitrong; Niong; Nitro-Bid; Nitroderm TTS; Trinitrosan; Rectogesic; Nitroglicerina; Cordipatch; Perglottal; Nitrorectal; Gilustenon; Nitroretard; Nitroplast; Corditrine; Trinitrolong; Adesitrin; Aldonitrin; Angibid; Angiolingual; Angiplex; Anglix; Angonist; Angorin; Anogesic; Buccal; Buccard; Cardabid; Cardamist; Cardinit; Cardiodisco; Cellegesic; Chitamite; Colenitral; Dauxona; Deponit; Diafusor; Discotrine; Dynamite; GTN; Glonoin; Glycerintrinitrate; Glyceroltrinitraat; Glyceryl; Glycerylnitrat; Glytrin; Herwicard; Herzer; Klavikordal; Lentonitrina; Millisrol; Minitram; Minitro; Mionitrat; Myocon; Myoglycerin; Myovin; NTG; Niglin; Niglycon; Nirmin; Nitora; Nitradisc; Nitrangin; Nitrek; Nitriderm; NitroBid; NitroCor; NitroDur; NitroMist; NitroQuick; NitroQuik; Nitroard; Nitrobaat; Nitrobukal; Nitrocap; Nitrocard; Nitrocerin; Nitroclyn; Nitrocontin; Nitrocot; Nitrodisc; Nitrodyl; Nitrogard; Nitrogliceryna; Nitroglin; Nitroject; Nitroletten; Nitrolin; Nitrolowe; Nitromel; Nitromex; Nitromint; Nitropatch; Nitropen; Nitropercuten; Nitroperlinit; Nitroprol; Nitropront; Nitroprontan; Nitrorex; Nitrostabilin; Nitrovis; Nysconitrine; Percutol; Perganit; Plastranit; Polnitrin; Ratiopharm; Soup; Suscard; Sustac; Sustak; TNG; Temponitrin; Trinalgon; Trinipatch; Triniplas; Trinitrol; Trinitron; Turicard; Vascana; Vasoglyn; Vasolator; Vernies; Willong; Blasting gelatin; Blasting oil; Gepan Nitroglicerin; Gilucor nitro; Glycerin trinitrate; Glycerine trinitrate; Glyceryl nitrate; NITRO IV; Neos nitro OPT; Niong Retard; Nitradisc Pad; Nitradisc TTS; Nitriderm TTS; Nitro Bid; Nitro Dur; Nitro Dur TTS; Nitro Mack Retard; Nitro Retard; Nitro Rorer; Nitrobid Oint; Nitrocontin Continus; Nitroderm TTS Ext; Nitrodyl TTS; Nitrol Ointment; Nitrolingual Spray; Nitromack Retard; Nitromint Aerosol; Nitromint Retard; Nitronal Aqueous; Nitrong Retard; Nitrong parenteral; Nitrozell retard; Percutol Oint; Spirit of glonoin; Tridil sublin; Trinitrin Tablets; Trinitrina Erba; Deponit 5; Deponit TTS 10; Deponit TTS 5; Nitrocine 5; Aquo-Trimitrosan; Coro-Nitro; Deponit-5; GTN-Pohl; IMX-150; MED-2002; MQX-503; Mi-Trates; Minitran (TN); NK-843; Natispray (TN); Nit-Ret; Nitrine-TDC; Nitro-Dur 10; Nitro-Dur 5; Nitro-Gesanit Retard; Nitro-Mack Retard; Nitro-Par; Nitro-Pflaster; Nitro-Span; Nitro-Time; Nitro-lent; NitrocapTD; Nitroderm TTS-5; Nitrogard-SR; Nitroglycerin (NG); Nitroglycerin-ACC; Nitrolingual Pump Spray (TN); Nitromist (TN); Nitrong-SR; Nitrospan (TN); Nitrostat (TN); SDM No 17; SK-106N; SK-866; SK-878; Top-Nitro; Transderm Nitro (TN); Transderm-N TTS; Transderm-Nitro TTS; Transiderm-nitro; Tridil (TN); Trinipatch (TN); Trinitrate, Glyceryl; Nitro-Dur (TN); Nitro-M-Bid; Nitro-bid (TN); Transderm-nitro (TN); DWP-401 Click to Show/Hide
MOA	Activator
External Link	CID: 4510 TTD: D07YDE DrugBank: DB00727
Compound Name	Epidermal growth factor		Approved	[9]
Synonyms	62229-50-9; Urogastrone; Uroenterone; Uroanthelone; Urogastron; Kutrol; beta-Urogastrone; Anthelone U; Urogastrone [JAN]; Gastrone, gamma-uro-; Gastrone, beta-uro- (human); Epidermal growth factor (egf); CCRIS 7234; EINECS 263-468-7; EPIDERMAL GROWTH FACTOR-UROGASTRONE; Gastrone, uro- (9CI); 9010-53-1; Gentel (TN); EGF Click to Show/Hide
MOA	Modulator
External Link	CID: 56841751 TTD: D08TPS
Compound Name	Osimertinib		Approved	[10]
Synonyms	Tagrisso Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 0.421 nM
External Link	CID: 71496458 TTD: D0O8GK DrugBank: DB09330
Compound Name	NERATINIB MALEATE		Approved	[11]
Synonyms	UNII-9RM7XY23ZS; 9RM7XY23ZS; Neratinib maleate [MI]; hki-272 maleate; Nerlynx (TN); SCHEMBL2180998; MolPort-044-561-003; AKOS030524209; DS-19892 Click to Show/Hide
MOA	Antagonist
External Link	CID: 67307512 TTD: D0U1ZV
Compound Name	Amivantamab		Approved	[12]
MOA	Inhibitor
External Link	TTD: DQ5X1Z
Compound Name	SKI-758		Approved	[13]
Synonyms	SCHEMBL3992463; CHEMBL219557; BDBM13047; 3-quinolinecarbonitrile analog 10; ANUHLKPVOXDYSK-UHFFFAOYSA-N; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]furan-3-yl}quinoline-3-carbonitrile; 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6 methoxy-7-{5-[(4-methylpiperazin-1-yl)methyl]-3-furyl}-3-quinolinecarbonitrile Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 230 nM
External Link	CID: 11341869 TTD: D03MNN
Compound Name	Dacomitinib		Approved	[9]
Synonyms	PF-00299804 Click to Show/Hide
MOA	Antagonist
Activity	IC50 = 1.8 nM
External Link	CID: 11511120 TTD: D06XXH DrugBank: DB11963
Compound Name	Lapatinib		Approved	[14]
Synonyms	FMM; Tycerb; Lapatinib Ditosylate; Lapatinib [INN]; Lapatinib tosilate hydrate; GSK 572016; GSK572016; GW 572016; GW 572016X; GW572016; Lapatinib (INN); Tykerb (TN); Lapatinib, Tykerb, GW572016; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; 4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; Lapatinib (ERBB2 inhibitor) Click to Show/Hide
MOA	Inhibitor
Activity	Ki = 3 nM
External Link	CID: 208908 TTD: D08CDI DrugBank: DB01259
Compound Name	Merimepodib		Approved	[15]
Synonyms	Merimebodib; Merimepodib [USAN:INN]; Tyverb/Tykerb; MMPD; 198821-22-6; 2ZL2BA06FU; C23H24N4O6; CHEMBL304087; MERIMEPODIB, VI-21497, VX-497; UNII-2ZL2BA06FU; VI-21497; VX-497; VX497; Vx 497; carbamic acid Click to Show/Hide
MOA	Inhibitor
External Link	CID: 153241 TTD: D0F0ZE DrugBank: DB04862
Compound Name	Vandetanib		Approved	[16]
Synonyms	Zactima; Vandetanib [INN]; CH 331; ZD 6474; ZD6474; AZD-6474; CH-331; F9995-0087; ZD-6474; Zactima, ZD6474; Vandetanib (JAN/INN); Vandetanib, Zactima, ZD6474; N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazolin-4-amine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine; N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine; 4-(4-Bromo-2-fluoroanilino)-6-methoxy-7-[(1-methylpiperidin-4-yl)methoxy]quinazoline; Vandetanib (Pan-TK inhibitor) Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 200 nM
External Link	CID: 3081361 TTD: D0G6QF DrugBank: DB05294
Compound Name	Sorafenib		Approved	[17]
Synonyms	Nexavar; Sorafenibum; Sorafenib [INN]; Nexavar (TN); Sorafenib (INN); N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; Sorafenib (Pan-TK inhibitor) Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 43.5 nM
External Link	CID: 216239 TTD: D0W5HK DrugBank: DB00398
Compound Name	Icotinib hydrochloride		Registered	[18]
Synonyms	Conmana; Conmanna; Icotinib; BPI-2009-H Click to Show/Hide
MOA	Antagonist
External Link	CID: 44609731 TTD: D06WRJ
Compound Name	Rindopepimut		Phase 3	[2]
MOA	Modulator
External Link	TTD: D05FRP
Compound Name	SYM-004		Phase 3	[19]
Synonyms	Chimeric IgG1 antibody 1024 (cancer), Symphogen; Chimeric IgG1 antibody 992 (cancer), Symphogen; Chimeric IgG1 antibodies992 + 1024 (cancer), Symphogen Click to Show/Hide
External Link	TTD: D0CR8H
Compound Name	DE-766		Phase 3	[9]
MOA	Modulator
External Link	TTD: D0FJ1W
Compound Name	EGF816		Phase 3	[20]
MOA	Inhibitor
Activity	IC50 = 160.6 nM
External Link	CID: 72703790 TTD: D0K7FY
Compound Name	CO-1686		Phase 3	[21]
Synonyms	1374640-70-6; AVL-301; CO1686; UNII-72AH61702G; CNX-419; CO-1686 (AVL-301); Rociletinib(AVL-301,CNX-419,CO-1686); 72AH61702G; N-(3-((2-((4-(4-acetylpiperazin-1-yl)-2-methoxyphenyl)amino)-5-(trifluoromethyl)pyrimidin-4-yl)amino)phenyl)acrylamide; CO 1686; Rociletinib (CO-1686, AVL-301); Rociletinib [USAN:INN]; Tube721; Rociletinib (USAN/INN); Rociletinib (CO-1686); SCHEMBL4177736; GTPL7966; CHEMBL3545308; EX-A228; MolPort-035-395-816; C27H28F3N7O3; HMS3653G08; BDBM149404; BCP07085; AOB87314; ZINC98043800; s7284 Click to Show/Hide
MOA	Modulator
Activity	IC50 = 1.6 nM
External Link	CID: 57335384 TTD: D0M4AV DrugBank: DB11907
Compound Name	Zalutumumab		Phase 3	[9]
External Link	TTD: D0R4PW
Compound Name	Almonertinib		Phase 3	[22]
Synonyms	HS-10296; Ameile; 1899921-05-1; Egfr T790M inhibitor HS-10296; N-(5-((4-(1-Cyclopropyl-1H-indol-3-yl)pyrimidin-2-yl)amino)-2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxyphenyl)acrylamide; UNII-T4RS462G19; SCHEMBL17683063; GTPL11136; T4RS462G19; EX-A3721; HS 10296 [WHO-DD]; s8817; HS10296; example 26 [WO2016054987A1]; HY-112823; CS-0066162; 2-Propenamide, N-(5-((4-(1-cyclopropyl-1H-indol-3-yl)-2-pyrimidinyl)amino)-2-((2-(dimethylamino)ethyl)methylamino)-4-methoxyphenyl)-; C1(CC1)N1C=C(C2=CC=CC=C12)C1=NC(=NC=C1)NC=1C(=CC(=C(C=1)NC(C=C)=O)N(C)CCN(C)C)OC; N-[5-[[4-(1-cyclopropylindol-3-yl)pyrimidin-2-yl]amino]-2-[2-(dimethylamino)ethyl-methylamino]-4-methoxyphenyl]prop-2-enamide Click to Show/Hide
MOA	Inhibitor
External Link	CID: 121280087 TTD: DDH8L6
Compound Name	ASP1929		Phase 3	[23]
Synonyms	Cetuximab sarotalocan Click to Show/Hide
MOA	Inhibitor
External Link	TTD: DWK96T
Compound Name	A140		Phase 3	[24]
External Link	TTD: DXZ31K
Compound Name	Bevacizumab + Erlotinib		Phase 3	[25]
MOA	Inhibitor
External Link	TTD: D09BKY
Compound Name	HKI-272		Phase 3	[26]
Synonyms	Neratinib (ERBB2 inhibitor) Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 0.08 nM
External Link	CID: 9915743 TTD: D0Q9CY DrugBank: DB11828
Compound Name	Indium-111		Phase 2/3	[27]
Synonyms	ABT-806 Click to Show/Hide
External Link	TTD: D0F3KC
Compound Name	Varlitinib		Phase 2/3	[28]
Synonyms	845272-21-1; ARRY-334543; ARRY334543; ARRY 334543; ARRY-543; UNII-846Y8197W1; ASLAN-001; 846Y8197W1; (R)-N4-(3-chloro-4-(thiazol-2-ylmethoxy)phenyl)-N6-(4-methyl-4,5-dihydrooxazol-2-yl)quinazoline-4,6-diamine; Varlitinib [USAN:INN]; Varlitinib (ARRY334543); Varlitinib free base; Varlitinib (USAN/INN); MLS006011274; GTPL7645; SCHEMBL1384578; CHEMBL2103842; SYN1192; MolPort-028-720-424; EX-A1005; 4-N-[3-chloro-4-(1,3-thiazol-2-ylmethoxy)phenyl]-6-N-[(4R)-4-methyl-4,5-dihydro-1,3-oxazol-2-yl]quinazoline-4,6-diamine Click to Show/Hide
MOA	Modulator
Activity	IC50 = 7 nM
External Link	CID: 42642648 TTD: D00NYJ DrugBank: DB05944
Compound Name	ASP8273		Phase 2	[29]
MOA	Inhibitor
Activity	IC50 = 8 nM
External Link	CID: 71667668 TTD: D02BYZ DrugBank: DB12036
Compound Name	ABT-414		Phase 2	[30]
External Link	TTD: D06XIT
Compound Name	Depatuxizumab		Phase 2	[31]
MOA	Antagonist
External Link	TTD: D0A6CC
Compound Name	Matuzumab		Phase 2	[32]
Synonyms	EMD-62000; EMD-72000; Anti-EGF receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-EGFR humanized mAb (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals; Anti-epidermal growth factor receptor humanized antibody (iv, cancer), Merck KGaA/ Takeda Pharmaceuticals Click to Show/Hide
External Link	TTD: D0BZ7V
Compound Name	HER1-VSSP vaccine		Phase 2	[33]
Synonyms	HER1-VSSP vaccine (cancer) Click to Show/Hide
External Link	TTD: D0C3LL
Compound Name	RM-1929		Phase 2	[34]
MOA	Antagonist
External Link	TTD: D0FN4T
Compound Name	CetuGEX		Phase 2	[35]
External Link	TTD: D0K9MC
Compound Name	ABX-EGF		Phase 2	[36]
External Link	TTD: D0P9RG
Compound Name	Pelitinib		Phase 2	[37]
Synonyms	EKB-569; EKI-569; WAY-EKB-569 Click to Show/Hide
MOA	Modulator
Activity	IC50 = 8.02 nM
External Link	CID: 6445562 TTD: D0S3PO DrugBank: DB05524
Compound Name	HM-78136B		Phase 2	[34]
Synonyms	Pan-Her/EGFR inhibitors (cancer), Hanmi Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 0.218 nM
External Link	CID: 25127713 TTD: D00YER DrugBank: DB12114
Compound Name	Pazopanib + Tyverb/Tykerb		Phase 2	[15]
MOA	Inhibitor
External Link	CID: 10113978 TTD: D03UKJ DrugBank: DB06589
Compound Name	MEHD-7945A		Phase 2	[28]
Synonyms	RG-7597; EGFR/HER3 dual monoclonal antibody, Genentech Click to Show/Hide
MOA	Modulator
External Link	TTD: D09BZJ
Compound Name	TT-100		Phase 2	[38]
Synonyms	TT-100, TriAct; Dual IGF-1/EGFR inhibitor (non-small-cell lung cancer), TriAct Click to Show/Hide
MOA	Inhibitor
External Link	TTD: D0T5JS
Compound Name	BMS-599626		Phase 2	[39]
Synonyms	714971-09-2; AC480; AC-480; BMS 599626; (S)-Morpholin-3-ylmethyl (4-((1-(3-fluorobenzyl)-1H-indazol-5-yl)amino)-5-methylpyrrolo[2,1-f][1,2,4]triazin-6-yl)carbamate; UNII-2252724U5N; CHEMBL1645462; BMS599626; AC480 (BMS-599626); 2252724U5N; J-502499; C27H27FN8O3; AC 480; AC1480 (free base); PubChem22432; GTPL7647; SCHEMBL12065349; CTK8B6780; DTXSID60221714; SYN1142; AOB5594; MolPort-023-279-418; EX-A2296; ZINC6717782; KS-000008GE; BDBM50333373; s1056; C27H44O11; ANW-54337; AKOS015999853; CS-0407; RL05125; BCP9000428; SB21703 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 32 nM
External Link	CID: 10437018 TTD: D0U4FF DrugBank: DB12318
Compound Name	Tarloxotinib		Phase 2	[40]
Synonyms	Tarloxotinib cation; UNII-H8768UL06V; H8768UL06V; [(E)-4-[[4-(3-bromo-4-chloroanilino)pyrido[3,4-d]pyrimidin-6-yl]amino]-4-oxobut-2-enyl]-dimethyl-[(3-methyl-5-nitroimidazol-4-yl)methyl]azanium; Tarloxotinib ion; GTPL9409; CHEMBL4297661; SCHEMBL19733352; PR610; DB14944; TH-4000; Q27279755; 1636938-13-0 Click to Show/Hide
MOA	Inhibitor
External Link	CID: 51038316 TTD: DUW81M DrugBank: DB14944
Compound Name	VATALANIB		Phase 2	[26]
Synonyms	212141-54-3; Vatalanib base; N-(4-chlorophenyl)-4-(pyridin-4-ylmethyl)phthalazin-1-amine; PTK787; Pynasunate; CGP 79787; Vatalanib free base; PTK-787; Vatalanib (free base); Vatalinib; ZK-232934; CGP-79787; ZK222584; PTK/ZK; CHEMBL101253; N-(4-Chlorophenyl)-4-(4-pyridinylmethyl)-1-phthalazinamine; UNII-5DX9U76296; CHEBI:90620; YCOYDOIWSSHVCK-UHFFFAOYSA-N; 1-(4-chloroanilino)-4-(4-pyridylmethyl)phthalazine; 5DX9U76296; NCGC00181350-01; 1-Phthalazinamine,N-(4-chlorophenyl)-4-(4-pyridinylmethyl)-; DSSTox_CID_26919 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 457.7 nM
External Link	CID: 151194 TTD: D0P6DJ DrugBank: DB04879
Compound Name	BMS-690514		Phase 2	[41]
Synonyms	BMS 690514; BMS690514 Click to Show/Hide
MOA	Inhibitor
External Link	CID: 11349170 TTD: D0R6UV DrugBank: DB11665
Compound Name	CI-1033		Phase 2	[16]
Synonyms	Canertinib; Canertinib HCl; Canertinib dihydrochloride; Canertinib dihydrochloride [USAN]; CI1033; PD 183805; Canertinib dihydrochloride (USAN); PD-0183805; PD-183805; Canertinib, PD-183805, CI1033, PD183805; N-[4-(3-Chloro-4-fluorophenylamino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]acrylamide dihydrochloride; N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[3-(4-morpholinyl)propoxy]-6-quinazolinyl]-2-propenamide dihydrochloride; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide; N-[4-(3-chloro-4-fluoroanilino)-7-(3-morpholin-4-ylpropoxy)quinazolin-6-yl]prop-2-enamide dihydrochloride; N-(4-(3-chloro-4-fluorophenyl)amino)-7-(3-morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide dihydrochloride; N-{4-[(3-chloro-4-fluorophenyl)amino]-7-[3-(morpholin-4-yl)propoxy]quinazolin-6-yl}prop-2-enamide; N-(4-((3-Chloro-4-fluorophenyl)amino)-7-(3-(morpholin-4-yl)propoxy)quinazolin-6-yl)prop-2-enamide; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl) amino)-7-(3-(4-morpholinyl) propoxy)-6-quinazolinyl)-, dihydrochloride; 2-Propenamide, N-(4-((3-chloro-4-fluorophenyl)amino)-7-(3-(4-morpholinyl)propoxy)-6-quinazolinyl)-, dihydrochloride Click to Show/Hide
MOA	Inhibitor
Activity	Ki = 0.11 nM
External Link	CID: 156414 TTD: D0YB3W DrugBank: DB05424
Compound Name	CART-EGFR		Phase 1/2	[42]
MOA	CAR-T-Cell-Therapy
External Link	TTD: D04DHZ
Compound Name	SN-32793		Phase 1/2	[9]
Synonyms	PR-509; PR-610; SN-32807; Hypoxia-activated irreversible pan-erbb inhibitors, Proacta; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer); Hypoxia-selective multi-kinase inhibitors (lung cancer), Proacta; Hypoxia-selective multi-kinase inhibitors(lung cancer), Proacta/ Yakult Honsha; Hypoxia-selective multi-kinase inhibitors (NSCLC resistant to reversible tyrosine kinase inhibitor/cancer), Proacta/ Yakult Honsha Click to Show/Hide
MOA	Inhibitor
External Link	TTD: D05ETC
Compound Name	EGFR CART		Phase 1/2	[43]
MOA	CAR-T-Cell-Therapy
External Link	TTD: D0G1ZU
Compound Name	EMD 55900		Phase 1/2	[36]
Synonyms	27686-84-6; 4,4'-((2R,3S)-2,3-Dimethylbutane-1,4-diyl)bis(benzene-1,2-diol); UNII-7BO8G1BYQU; 1,2-Benzenediol, 4,4'-(2,3-dimethyl-1,4-butanediyl)bis-, (R,S)-; EINECS 248-606-6; 7BO8G1BYQU; CHEMBL313972; erythro-nordihydroguaiaretic acid; CHEBI:73468 Click to Show/Hide
External Link	TTD: D0S8BG
Compound Name	TAK-186		Phase 1/2	[44]
MOA	Inhibitor
External Link	TTD: DC1GH7
Compound Name	ZN-e4		Phase 1/2	[45]
MOA	Inhibitor
External Link	TTD: DF0PR6
Compound Name	EMB-01		Phase 1/2	[46]
MOA	Inhibitor
External Link	TTD: DWQ6J1
Compound Name	Sym015		Phase 1/2	[31]
MOA	Antagonist
External Link	TTD: D0B4OK
Compound Name	BDTX-189		Phase 1/2	[47]
Synonyms	2414572-47-5; EX-A4379 Click to Show/Hide
MOA	Inhibitor
External Link	CID: 154824631 TTD: D9FJ5V
Compound Name	AFM24		Phase 1/2	[48]
External Link	TTD: DK8QG3
Compound Name	Sym013		Phase 1/2	[31]
MOA	Antagonist
External Link	TTD: D0FF2G
Compound Name	S-222611		Phase 1b	[49]
MOA	Inhibitor
External Link	TTD: D0V4XY
Compound Name	SYN004		Phase 1	[31]
MOA	Inhibitor
External Link	TTD: D00KML
Compound Name	BIBX-1382		Phase 1	[50]
Synonyms	Falnidamol; BIBX 1382; 196612-93-8; BIBX1382; UNII-0MU316797D; CHEMBL258940; FTFRZXFNZVCRSK-UHFFFAOYSA-N; 0MU316797D; N8-(3-Chloro-4-fluorophenyl)-N2-(1-methylpiperidin-4-yl)pyrimido[5,4-d]pyrimidine-2,8-diamine; Bibx 1382bs; Falnidamol [INN]; NCGC00161422-01; AC1OCFIP; BIBX-1382BX; BIBX-1382BS; SCHEMBL158563; GTPL7646; DTXSID0048399; CHEBI:93243; EX-A570; AOB5489; MolPort-039-136-623; ZINC1494443; KS-00001CR9; BCP09515; BDBM50375639; AKOS025396660; API0007916; DB12966; CS-0691; NCGC00161422-03; AS-16894; HY-10322; AK174047 Click to Show/Hide
MOA	Antagonist
Activity	IC50 = 3 nM
External Link	CID: 6918508 TTD: D00RMC DrugBank: DB12966
Compound Name	IMGN289		Phase 1	[51]
MOA	Inhibitor
External Link	TTD: D04HSH
Compound Name	AST-1306		Phase 1	[52]
Synonyms	Allitinib; Allitinib tosylate Click to Show/Hide
MOA	Modulator
External Link	CID: 24739943 TTD: D04OLK
Compound Name	AMG 595		Phase 1	[53]
MOA	Modulator
External Link	TTD: D05LMC
Compound Name	HER-2/HER-1 vaccine		Phase 1	[9]
Synonyms	HER-2/HER-1 vaccine (solid tumors) Click to Show/Hide
External Link	TTD: D0E7RC
Compound Name	EGFR806-specific CAR T cell		Phase 1	[54]
MOA	CAR-T-Cell-Therapy
External Link	TTD: D0I7ZH
Compound Name	PF-05230907		Phase 1	[55]
MOA	Inhibitor
External Link	TTD: D0JS0W
Compound Name	MR1-1		Phase 1	[56]
Synonyms	MR1-1KDEL; EGFR-specific immunotoxin, IVAX; Anticancer immunotoxin (EGFR-specific), IVAX Click to Show/Hide
MOA	Modulator
External Link	TTD: D0N3PC
Compound Name	Anti-EGFR CAR T		Phase 1	[57]
MOA	CAR-T-Cell-Therapy
External Link	TTD: D0T0SE
Compound Name	AP32788		Phase 1	[34]
MOA	Inhibitor
External Link	TTD: D0X7BN
Compound Name	CLN-081		Phase 1	[58]
MOA	Inhibitor
External Link	TTD: D68RMI
Compound Name	LY3164530		Phase 1	[59]
MOA	Modulator
External Link	TTD: D01IJM
Compound Name	MM-151		Phase 1	[31]
MOA	Antagonist
External Link	TTD: D01NAP
Compound Name	Cipatinib		Phase 1	[28]
Synonyms	HER-1/HER-2 inhibitor (oral, cancer), Jiangsu Hengrui Click to Show/Hide
MOA	Modulator
External Link	TTD: D08JAN
Compound Name	Anti-HER3/EGFR DAF		Phase 1	[60]
MOA	Modulator
External Link	TTD: D0JW2O
Compound Name	BCA101		Phase 1	[61]
MOA	Inhibitor
External Link	TTD: D0U7XJ
Compound Name	CUDC-101		Phase 1	[62]
Synonyms	1012054-59-9; CUDC 101; CUDC101; 7-(4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yloxy)-N-hydroxyheptanamide; UNII-1A7Y9MP123; CHEMBL598797; 1A7Y9MP123; 7-[[4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl]oxy]-N-hydroxyheptanamide; AK174946; 7-((4-(3-Ethynylphenylamino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; 7-({4-[(3-ethynylphenyl)amino]-7-methoxyquinazolin-6-yl}oxy)-N-hydroxyheptanamide; 7-((4-((3-ethynylphenyl)amino)-7-methoxyquinazolin-6-yl)oxy)-N-hydroxyheptanamide; PubChem19149 Click to Show/Hide
MOA	Modulator
Activity	IC50 = 2.4 nM
External Link	CID: 24756910 TTD: D0Z4RC DrugBank: DB12174
Compound Name	SI-B001		Phase 1	[63]
External Link	TTD: D6JM8Z
Compound Name	CX-904		Phase 1	[64]
Synonyms	AMG 651 Click to Show/Hide
External Link	TTD: D73FNL
Compound Name	AZD9592		Phase 1	[65]
External Link	TTD: DN47VK
Compound Name	D2C7		Phase 1	[66]
External Link	TTD: DR4ND6
Compound Name	MCLA-158		Phase 1	[67]
MOA	Inhibitor
External Link	TTD: DV8I4Q
Compound Name	JNJ-26483327		Phase 1	[68]
Synonyms	MTKI (cancer), J&J; MTKI (cancer), Johnson & Johnson; Multi-targeted kinase inhibitor (cancer), J&J; Multi-targeted kinase inhibitor (cancer), Johnson & Johnson Click to Show/Hide
MOA	Inhibitor
External Link	TTD: D0U3XL
Compound Name	Pyrrolo[2,3-d]pyrimidine derivative 24		Patented	[69]
Synonyms	PMID28705083-Compound-22 Click to Show/Hide
MOA	Inhibitor
External Link	CID: 90468938 TTD: D0Z2PC
Compound Name	PKI166		Discontinued in Phase 2	[70]
Synonyms	PKI-166; CGP-75166; 187724-61-4; NVP-PKI166; CHEMBL1914653; AC1OCFE0; UNII-9RIE5HW38P; 9RIE5HW38P; SCHEMBL177814; GTPL7642; CHEMBL1963502; ZINC23255; AOB1619; PKI-75166; BDBM50358046; NCGC00387215-02; AS-16676; KB-275097; PKI-166, > 4-[4-[[(1R)-1-phenylethyl]amino]-7H-pyrrolo[4,5-e]pyrimidin-6-yl]phenol Click to Show/Hide
MOA	Modulator
Activity	IC50 = 3.7 nM
External Link	CID: 6918403 TTD: D07GFF
Compound Name	RG7160		Discontinued in Phase 2	[71]
MOA	Modulator
External Link	TTD: D0E2CQ
Compound Name	PD-153035		Discontinued in Phase 1	[72]
Synonyms	183322-45-4; PD153035 hydrochloride; N-(3-Bromophenyl)-6,7-dimethoxyquinazolin-4-amine hydrochloride; PD153035 HCl; PD 153035 HYDROCHLORIDE; PD-153035 hydrochloride; PD153035 (Hydrochloride); Tyrphostin AG 1517; AG 1517 hydrochloride; SU-5271 hydrochloride; UNII-AHJ252P69N; ZM 252868; SU 5271; AG 1517; 4-[(3-BROMOPHENYL)AMINO]-6,7-DIMETHOXYQUINAZOLINE HYDROCHLORIDE; AHJ252P69N; pd 153035; PD153035.HCl; CHEMBL1204168; 6,7-Dimethoxy-4-[N-(3-bromophenyl)amino]quinazoline hydrochloride; C16H15BrClN3O2; 4-Quinazolinamine, N-(3-bromo Click to Show/Hide
MOA	Modulator
Activity	Ki = 0.006 nM
External Link	CID: 4705 TTD: D0Q7HO
Compound Name	AZD4769		Discontinued in Phase 1	[73]
Synonyms	Acetic acid, ((4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)-; 127481-29-2; L-674573; ((4-Phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl)thio)acetic acid; {[4-phenyl-1-(4-(2-quinolinylmethoxy)phenyl)butyl]thio}acetic acid; L 674573; L-674,573; AC1L3YFJ; SCHEMBL9460146; CHEMBL422872; JOIXGLLMSDPZDN-UHFFFAOYSA-N; AZD-4769; 2-[[4-phenyl-1-[4-(2-quinolinylmethoxy)phenyl]butyl]thio]Acetic acid; DA-13018; FT-0734991; AZ-12096971; 2-[4-phenyl-1-[4-(quinolin-2-ylmethoxy)phenyl]butyl]sulfanylacetic Click to Show/Hide
MOA	Inhibitor
External Link	CID: 124437 TTD: D02RZL
Compound Name	TAK165		Discontinued in Phase 1	[16]
Synonyms	Mubritinib; TAK 165; Mubritinib (USAN/INN); 4-[[4-[4-(triazol-1-yl)butyl]phenoxy]methyl]-2-[(E)-2-[4-(trifluoromethyl)phenyl]ethenyl]-1,3-oxazole Click to Show/Hide
MOA	Inhibitor
External Link	CID: 6444692 TTD: D0A9OV DrugBank: DB12682
Compound Name	111In-hEGF		Preclinical	[74]
Synonyms	Indium-111-hEGF; Indium-111-labeled human epithelial growth factor (breast cancer), University of Toronto; 111In-labeledhuman epithelial growth factor (breast cancer), University of Toronto Click to Show/Hide
MOA	Modulator
External Link	TTD: D0V2FZ
Compound Name	EGFR/IGFR tandem adnectin		Preclinical	[75]
Synonyms	BMS-964210 Click to Show/Hide
MOA	Inhibitor
External Link	TTD: D0TI4U
Compound Name	Heparin-EGF-like factor		Terminated	[76]
Synonyms	HB-EGF, Scios Nova; Heparin-EGF-like factor, Scios Nova Click to Show/Hide
MOA	Modulator
External Link	TTD: D02GFZ
Compound Name	CGP-52411		Terminated	[77]
Synonyms	DAPH Click to Show/Hide
MOA	Inhibitor
Activity	Ki = 160 nM
External Link	CID: 1697 TTD: D03QTP
Compound Name	CGP-53353		Terminated	[78]
Synonyms	145915-60-2; CGP 53353; DAPH 2; DAPH-7; CGP53353; PKCbetaII/EGFR Inhibitor; 5,6-BIS[(4-FLUOROPHENYL)AMINO]-1H-ISOINDOLE-1,3(2H)-DIONE; CHEMBL7939; CGP 53 353; 4,5-bis(4-Fluoroanilino)-phthalimide; CG53353; 5,6-Bis((4-fluorophenyl)amino)isoindoline-1,3-dione; 5,6-Bis[(4-fluorophenyl)amino]-2H-isoindole-1,3-dione; 4,5-Bis(4-fluoroanilino)phthalimide; 4,5-Bis[4-fluoroanilino]phthalimide; PKCbII/EGFR Inhibitor; AC1O8KXF; 5,6-bis(4-fluoroanilino)isoindole-1,3-dione; MolMap_000016; DAPH-2; CGP-53353, solid; SCHEMBL230492 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 700 nM
External Link	CID: 6711154 TTD: D0HO1S
Compound Name	AZD-9935		Terminated	[79]
MOA	Antagonist
External Link	TTD: D0Y1YX
Compound Name	N4-(3-chlorophenyl)quinazoline-4,6-diamine		Investigative	[80]
Synonyms	CHEMBL343352; Anilinoquinazoline, 4c; SCHEMBL1262804; AWAYNEMCHILZCF-UHFFFAOYSA-N; ZINC13527446; BDBM50133382; AKOS013915036; 6-amino-4-(3'-chloroanilino)quinazoline; N4-(3-chlorophenyl)-4,6-quinazolinediamine; 6-amino-4[(3-chlorophenyl)amino]quinazoline Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 3.38 nM
External Link	CID: 11807783 TTD: D00TJF
Compound Name	2-benzoyl-3-(3,4-dihydroxyphenyl)acrylonitrile		Investigative	[81]
Synonyms	Tyrphostin deriv. 29; AC1NS5AC; CHEMBL56132; BDBM4296; ZINC12352646; 2-(Benzoyl)-3-(3,4-dihydroxyphenyl)acrylonitrile; (E)-2-benzoyl-3-(3,4-dihydroxyphenyl)prop-2-enenitrile Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 1000 nM
External Link	CID: 5328763 TTD: D00VZA
Compound Name	6,7-dimethoxy-4-(3-phenoxyprop-1-ynyl)quinazoline		Investigative	[82]
Synonyms	CHEMBL250523; BDBM50222432 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 15 nM
External Link	CID: 44442168 TTD: D00WZG
Compound Name	2-cyano-3-(3,4-dihydroxyphenyl)acrylamide		Investigative	[81]
Synonyms	Tyrphostin 46; Tyrphostin A46; AG 99; Tyrphostin B40; 122520-85-8; alpha-Cyano-(3,4-dihydroxy)cinnamide; AG-99; 3,4-Dihydroxy-alpha-cyanocinnamamide; UNII-ARL2OF9022; CHEMBL296407; ARL2OF9022; 118409-59-9; Tyrphostin AG 99; (E)-2-cyano-3-(3,4-dihydroxyphenyl)prop-2-enamide; NSC666250; NSC-666250; 2-Propenamide, 2-cyano-3-(3,4-dihydroxyphenyl)-; (~{E})-3-[3,4-bis(oxidanyl)phenyl]-2-cyano-prop-2-enamide; Tyrphostin AG99; 3,4-Dihydroxy-alpha-cyanocinnamide; NSC 666250; Tocris-0497; Tyrphostin deriv. 40; BiomolKI_000013; AC1NS5AR Click to Show/Hide
MOA	Inhibitor
Activity	Ki = 3500 nM
External Link	CID: 5328768 TTD: D01NTW
Compound Name	HM-61713B		Investigative	[9]
Synonyms	EGFR mutant selective inhibitor (cancer), Hanmi; EMSI (cancer), Hanmi Click to Show/Hide
MOA	Inhibitor
External Link	TTD: D01SQP
Compound Name	Benzyl-quinazolin-4-yl-amine		Investigative	[83]
Synonyms	N-Benzylquinazolin-4-amine; N-benzyl-N-(4-quinazolinyl)amine; 4-(Benzylamino)quinazoline; 100818-54-0; 4-Benzylaminoquinazoline; AC1LDDI3; benzylquinazolin-4-ylamine; ChemDiv2_003678; N-benzyl-4-quinazolineamine; Oprea1_089836; MLS000701321; N-Benzyl-4-quinazolinamine #; cid_616573; CHEMBL102726; BDBM3256; SCHEMBL7612718; CHEBI:92768; MolPort-001-960-903; FVWANTDQRFSCAL-UHFFFAOYSA-N; HMS2233F15; HMS3373H15; HMS1379H04; ZINC109589; 4-[(phenylmethyl)amino]quinazoline; N-(phenylmethyl)-4-quinazolinamine Click to Show/Hide
MOA	Inhibitor
External Link	CID: 6603129 TTD: D01WDI
Compound Name	6,7-diethoxy-4-styrylquinazoline		Investigative	[82]
Synonyms	CHEMBL250925 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 15 nM
External Link	CID: 44442181 TTD: D01WXV
Compound Name	AFM-21		Investigative	[9]
Synonyms	Anti-EGFR antibody (RECRUIT-TandAb, colon/solid tumors), Affimed Click to Show/Hide
External Link	TTD: D02FGG
Compound Name	PD182905		Investigative	[84]
MOA	Inhibitor
External Link	TTD: D02GCE
Compound Name	AG 112		Investigative	[85]
Synonyms	tyrphostin A48; tyrphostin AG 112; AG-112; AG112 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 125 nM
External Link	CID: 5328804 TTD: D02KVB
Compound Name	2-(4,5-Dihydroxy-indan-1-ylidene)-malononitrile		Investigative	[86]
Synonyms	(4,5-Dihydroxyindanylidene)malononitrile; Tyrphostin deriv. 17; AC1NS59O; CHEMBL57300; BDBM4286; 133550-13-7; 2-(4,5-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; 2-(4,5-dihydroxy-2,3-dihydro-1H-inden-1-ylidene)propanedinitrile Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 7000 nM
External Link	CID: 5328755 TTD: D02RIG
Compound Name	(3-Bromo-phenyl)-quinazolin-4-yl-amine		Investigative	[87]
Synonyms	N-(3-bromophenyl)quinazolin-4-amine; CHEMBL290096; AC1LEF72; SCHEMBL2992623; BDBM3264; 4-Anilino quinazoline deriv. 15; ZINC151213; (3-bromophenyl)quinazolin-4-ylamine; N-(3-Bromophenyl)-4-quinazolinamine; AKOS002264782; MCULE-4660970870; 4-Quinazolinamine, N-(3-bromophenyl)- Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 27 nM
External Link	CID: 735125 TTD: D02ZRO
Compound Name	PD-158780		Investigative	[88]
Synonyms	171179-06-9; PD158780; pd 158780; N4-(3-bromophenyl)-N6-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AC1L1IRV; CHEMBL53753; 4-N-(3-bromophenyl)-6-N-methylpyrido[3,4-d]pyrimidine-4,6-diamine; AK160389; 4-(3-bromoanilino)-6-methylaminopyrido[3,4-d]pyrimidine; 4-[(3-bromophenyl)amino]-6-(methylamino)pyrido[3,4-d]pyrimidine; 4-[(3-Bromophenyl)amino]-6-(methylamino)-pyrido[3,4-d]pyridimine; Pyrido[3,4-d]pyrimidine-4,6-diamine, N4-(3-bromophenyl)-N6-methyl- Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 0.008 nM
External Link	CID: 4707 TTD: D03ATU
Compound Name	EGFR inhibitor		Investigative	[89]
Synonyms	879127-07-8; CHEMBL387187; N-(3-((6-((3-(Trifluoromethyl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)cyclopropanecarboxamide; Cyclopropanecarboxylic acid-(3-(6-(3-trifluoromethyl-phenylamino)-pyrimidin-4-ylamino)-phenyl)-amide; K00598a; N-{3-[(6-{[3-(trifluoromethyl)phenyl]amino}pyrimidin-4-yl)amino]phenyl}cyclopropanecarboxamide; EGFR Inhibitor 324674; SCHEMBL242230; GTPL5963; CTK8E9808; DTXSID40429554; MolPort-042-665-758; HMS3229E03; BDBM50200394; ZINC13831337; API0010446; CCG-206749; NCGC00167954-01 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 21 nM
External Link	CID: 9549299 TTD: D03BJB
Compound Name	6,7-diethoxy-4-(4-phenylbut-1-enyl)quinazoline		Investigative	[82]
Synonyms	CHEMBL399371 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 5 nM
External Link	CID: 44442182 TTD: D03CVQ
Compound Name	LA22-radioimmunoconjugates		Investigative	[9]
Synonyms	LA22-radioimmunoconjugates (cancer); Lutetium177-DOTA-LA22; LA22-radioimmunoconjugates (cancer), Welson/PekingUniversity; MAb-conjugated radioimmunotherapeutics (cancer), Welson/Peking University; 177Lu-DOTA-LA22; 177Lu-DTPA-LA22 Click to Show/Hide
MOA	Modulator
External Link	TTD: D03MTY
Compound Name	5-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide		Investigative	[90]
Synonyms	CHEMBL382537 Click to Show/Hide
MOA	Inhibitor
External Link	CID: 11717472 TTD: D03WEN
Compound Name	ICR 62		Investigative	[36]
External Link	TTD: D03ZIW
Compound Name	Bmab-200		Investigative	[9]
Synonyms	Anti-EGFR mAb (cancer), Biocon; Anti-epidermal growth factor receptor monoclonal antibody (cancer), Biocon Click to Show/Hide
External Link	TTD: D04GCH
Compound Name	HTS-00213		Investigative	[91]
Synonyms	CHEMBL461781; AC1MDDFE; MolPort-002-900-007; ZINC1028479; BDBM50292742; MCULE-3257779074; 3-((2,6-dichlorophenoxy)methyl)-5-((4-(4-(trifluoromethyl)phenyl)-4H-1,2,4-triazol-3-ylthio)methyl)-1,2,4-oxadiazole Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 6300 nM
External Link	CID: 2809539 TTD: D04HGN
Compound Name	6,7-diethoxy-4-(5-phenylpent-1-enyl)quinazoline		Investigative	[82]
Synonyms	CHEMBL251123 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 140 nM
External Link	CID: 44442183 TTD: D04LXG
Compound Name	N4-Benzyl-pyrido[4,3-d]pyrimidine-4,7-diamine		Investigative	[88]
Synonyms	CHEMBL300083; 4-N-benzylpyrido[4,3-d]pyrimidine-4,7-diamine; 7-Aminopyrido[4,3-d]pyrimidine 8a; AC1NS3PZ; SCHEMBL6839398; BDBM3331; pyrido[4,3-d]pyrimidine-4,7-diamine,n4-(phenylmethyl)-; ZINC3815364; 171178-89-5; PD-69896; KB-302882 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 578 nM
External Link	CID: 5328077 TTD: D05ARF
Compound Name	Epitinib		Investigative	[9]
Synonyms	HMPL-813; EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma Click to Show/Hide
MOA	Inhibitor
External Link	CID: 59142777 TTD: D05MEY
Compound Name	OSI-75		Investigative	[92]
MOA	Inhibitor
External Link	TTD: D06QEQ
Compound Name	(E)-5-(4-Hydroxybenzylidene)-1-phenethylhydantoin		Investigative	[93]
Synonyms	CHEMBL213560; SCHEMBL16693054; BDBM50187134 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 710 nM
External Link	CID: 15984068 TTD: D06UEK
Compound Name	HTS-02876		Investigative	[91]
Synonyms	AC1MDGL2; CHEMBL460914; MolPort-002-900-576; ZINC1030761; MCULE-7093116609 Click to Show/Hide
MOA	Inhibitor
External Link	CID: 2810910 TTD: D07CZM
Compound Name	2-(5,6-Dihydroxy-indan-1-ylidene)-malononitrile		Investigative	[86]
Synonyms	133550-11-5; Propanedinitrile, (2,3-dihydro-5,6-dihydroxy-1H-inden-1-ylidene)-; Tyrphostin deriv. 15; ACMC-20muzh; AC1NS59I; SCHEMBL6285970; CHEMBL293584; BDBM4284; CTK0C0328; DTXSID30416170; 2-(5,6-dihydroxy-2,3-dihydroinden-1-ylidene)propanedinitrile; (5,6-Dihydroxyindanylidene)malononitrile; [(2,3-Dihydro-5,6-dihydroxy-1H-inden)-1-ylidene]malononitrile Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 500 nM
External Link	CID: 5328753 TTD: D07IHD
Compound Name	PMID8568816C56		Investigative	[94]
Synonyms	PD153035 Analog 56; 171745-13-4; AC1L1EMN; K00042; BDBM3556; GTPL5956; CTK6G1384; DTXSID40274389; MolPort-019-910-218; HMS3229C09; BCP08039; ZINC2572485; IN1496; CCG-206742; QC-8197; ACM171745134; RT-012080; SR-02000000170; SR-02000000170-1; J-010 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 0.006 nM
External Link	CID: 2857 TTD: D07UYV
Compound Name	MT-062		Investigative	[9]
Synonyms	EGFR inhibitor (melanoma), Medisyn Technologies Click to Show/Hide
MOA	Inhibitor
External Link	TTD: D08RXW
Compound Name	Anti-EGFR mab		Investigative	[9]
External Link	TTD: D09RXX
Compound Name	RG-50810		Investigative	[81]
Synonyms	Tyrphostin 23; 118409-57-7; Tyrphostin A23; AG 18; (3,4-Dihydroxybenzylidene)malononitrile; AG-18; Tyrphostin AG18; Tyrphostin RG50810; 2-(3,4-dihydroxybenzylidene)malononitrile; UNII-RV0GCD31OJ; alpha-Cyano-(3,4-dihydroxy)cinnamonitrile; 2-[(3,4-dihydroxyphenyl)methylidene]propanedinitrile; RG 50810; Propanedinitrile,2-[(3,4-dihydroxyphenyl)methylene]-; ag18; (3,4-Dihydroxyphenyl)methylene propanedinitrile; RV0GCD31OJ; C10H6N2O2; NCGC00016043-03; (3,4-dihydroxybenzylidene)propanedinitrile; DSSTox_CID_25215 Click to Show/Hide
MOA	Inhibitor
Activity	Ki = 11000 nM
External Link	CID: 2052 TTD: D0A0JL
Compound Name	IPS-01003		Investigative	[9]
Synonyms	EGFR kinase antagonist (cancer), InnoPharmaScreen Click to Show/Hide
MOA	Antagonist
External Link	TTD: D0AC7C
Compound Name	RM-6427		Investigative	[9]
Synonyms	RM-6428; EGFR tyrosine kinase inhibitors (parasitic infection), Romark Click to Show/Hide
MOA	Inhibitor
External Link	CID: 9931101 TTD: D0AH2V
Compound Name	N4-(3-Bromo-phenyl)-quinazoline-4,6,7-triamine		Investigative	[87]
Synonyms	bpdq; CHEMBL328216; 4-N-(3-bromophenyl)quinazoline-4,6,7-triamine; 4-[(3-Bromophenyl)amino]-6,7-diaminoquinazoline; 169205-87-2; AC1L1DNE; N4-(3-bromophenyl)-4,6,7-Quinazolinetriamine; K00041; SCHEMBL7221302; BDBM3303; 4-Anilinoquinazoline deriv. 54; CTK8F8323; ADXSZLCTQCWMTE-UHFFFAOYSA-N; IN1401; HSCI1_000040; AKOS025149794; 4-(3-bromoanilino)-6,7-diaminoquinazoline; N-(3-Bromophenyl)quinazoline-4,6,7-triamine; 4[ (3-Bromophenyl)aminol-6,7-diaminoquinazoline; J-010514 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 0.12 nM
External Link	CID: 2426 TTD: D0B4PH
Compound Name	3-Pyridin-4-yl-quinoline-6,7-diol		Investigative	[95]
MOA	Inhibitor
Activity	IC50 = 5000 nM
External Link	CID: 135469328 TTD: D0B8DE
Compound Name	AGT-2000		Investigative	[9]
Synonyms	Gene therapy (intravenous, brain cancer), ArmaGen Click to Show/Hide
MOA	Modulator
External Link	TTD: D0C5WE
Compound Name	3-(3-Chloro-phenyl)-5,7-dihydroxy-chromen-4-one		Investigative	[96]
Synonyms	CHEMBL7827; SCHEMBL3355884; 62845-10-7; CTK2B1467; ZINC23489; DTXSID10445847; BDBM50074745; AKOS030553076; 5,7-Dihydroxy-3-(3-chlorophenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 3-(3-chlorophenyl)-5,7-dihydroxy- Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 95 nM
External Link	CID: 10850934 TTD: D0C9KC
Compound Name	ON-128		Investigative	[9]
Synonyms	ON-128060; ON-128 series (cancer); HER1/EGFR inhibitors (cancer), Onconova; Human epidermal growth factor receptor 1/epidermal growth factor receptor inhibitors (cancer), Onconova; ON-128 series (cancer), Onconova Click to Show/Hide
MOA	Inhibitor
External Link	TTD: D0CY9O
Compound Name	FHT-2107		Investigative	[9]
Synonyms	EGFR-targeting siRNA agent, ForHumanTech Click to Show/Hide
External Link	TTD: D0D0GS
Compound Name	GI-3000		Investigative	[9]
Synonyms	GI-3001; GI-6200; GlioVax-1; EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen); EGFR-expressing Saccharomyces cerevisiae-based cancer vaccine (Tarmogen), GlobeImmune Click to Show/Hide
External Link	TTD: D0D0YK
Compound Name	6,7-dimethoxy-N-m-tolylquinazolin-4-amine		Investigative	[91]
Synonyms	CHEMBL56802; AC1MDC5E; Oprea1_570563; SCHEMBL5482883; ZINC5857; 4-Quinazolinamine,6,7-dimethoxy-N-(3-methylphenyl)-; MolPort-001-734-434; BDBM50102093; MCULE-3929709513; 666839-07-2; (6,7-Dimethoxy-quinazolin-4-yl)-m-tolyl-amine; SR-02000000178; SR-02000000178-1; 6,7-dimethoxy-N-(3-methylphenyl)quinazolin-4-amine Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 4.6 nM
External Link	CID: 2808977 TTD: D0DF3Z
Compound Name	5,6-Bis-p-tolylamino-isoindole-1,3-dione		Investigative	[78]
Synonyms	CHEMBL7914; SCHEMBL8834183; BDBM50040920 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 4500 nM
External Link	CID: 10360970 TTD: D0EH6L
Compound Name	HTS-05058		Investigative	[89]
Synonyms	MLS000327715; SMR000180717; 3-(1H-imidazol-5-ylmethylene)-1,3-dihydro-2H-indol-2-one; (3Z)-3-(1H-imidazol-5-ylmethylidene)-1H-indol-2-one; Angiogenesis Inhibitor; 372164-79-9; AC1NWWY9; CHEMBL261692; SCHEMBL2998484; REGID_for_CID_667701; BDBM41079; cid_5714572; REGID_for_CID_5714572; MolPort-002-870-304; MolPort-002-901-109; HMS2463B12; ZINC4693510; AKOS015992864; (3Z)-3-(1H-imidazol-5-ylmethylene)oxindole; 4X-0884; J-011988 Click to Show/Hide
MOA	Inhibitor
External Link	CID: 5714572 TTD: D0EP1G
Compound Name	N-(4-m-Tolylamino-quinazolin-7-yl)-acrylamide		Investigative	[97]
Synonyms	CHEMBL297968; SCHEMBL2994207; FAGJCAQBJKSOOS-UHFFFAOYSA-N; BDBM50077245; N-[4-(3-Methylanilino)quinazoline-7-yl]acrylamide Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 90 nM
External Link	CID: 10494722 TTD: D0F6FZ
Compound Name	4-(4-(2-nitrovinyl)phenoxysulfonyl)benzoic acid		Investigative	[81]
Synonyms	CHEMBL76958; BDBM50007075; 4-[4-(2-Nitro-vinyl)-phenoxysulfonyl]-benzoic acid; 4-[4-[(E)-2-Nitroethenyl]phenoxysulfonyl]benzoic acid Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 1000 nM
External Link	CID: 14862522 TTD: D0G4HR
Compound Name	Benzo[g]quinazolin-4-yl-(3-bromo-phenyl)-amine		Investigative	[87]
Synonyms	CHEMBL63786; N-(3-bromophenyl)benzo[g]quinazolin-4-amine; Benzoquinazoline deriv. 23; AC1NS43R; SCHEMBL4348523; BDBM3585; BUVKJPOCMOXSSQ-UHFFFAOYSA-; ZINC3815025; 4-[(3-Bromophenyl)amino]benzo[g]quinazoline; N-(3-Bromophenyl)benzo[g]quinazoline-4-amine Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 0.003 nM
External Link	CID: 5328245 TTD: D0G9KD
Compound Name	ARX-AHD		Investigative	[9]
Synonyms	Dolastatin-conjugated HER2 antibody (breast cancer), Ambrx Click to Show/Hide
External Link	TTD: D0GB7F
Compound Name	TGF alpha		Investigative	[9]
Synonyms	TGF alpha (neurological damage) Click to Show/Hide
MOA	Modulator
External Link	TTD: D0H3FX
Compound Name	AG 9		Investigative	[85]
Synonyms	tyrphostin 1; tyrphostin A1; AG9; AG-9 Click to Show/Hide
MOA	Inhibitor
Activity	Ki > 400000 nM
External Link	CID: 2063 TTD: D0H3UI
Compound Name	N4-(3-Bromo-phenyl)-quinazoline-4,6-diamine		Investigative	[98]
Synonyms	N4-(3-Bromophenyl)quinazoline-4,6-diamine; 169205-78-1; 4-N-(3-bromophenyl)quinazoline-4,6-diamine; CHEMBL52765; AK-25174; N4-(3-bromophenyl)-4,6-quinazolinediamine; 4,6-Quinazolinediamine, N4-(3-bromophenyl)-; C14H11BrN4; nchembio866-comp32; Anilinoquinazoline, 4b; AC1NS3N2; BDBM3294; SCHEMBL1417740; 4-Anilinoquinazoline deriv. 45; KS-00000HMR; CTK4D3225; DTXSID40416141; IZQHULBHKPGOAP-UHFFFAOYSA-N; MolPort-009-198-483; ZINC3815034; BCP18882; ANW-50332; AKOS013915836; 6-amino 4-(3-bromoanilino)quinazoline; GS-4221 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 0.78 nM
External Link	CID: 5328042 TTD: D0HM5W
Compound Name	4-(5-Bromoindole-3-yl)-6,7-dimethoxyquinazoline		Investigative	[99]
Synonyms	CHEMBL473320; SCHEMBL5616932 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 131 nM
External Link	CID: 11696664 TTD: D0I7RA
Compound Name	Theliatinib		Investigative	[9]
Synonyms	HMPL-309; Second EGFR tyrosine kinase inhibitor (cancer), Hutchison Medipharma Click to Show/Hide
MOA	Inhibitor
External Link	CID: 54759275 TTD: D0J3EA
Compound Name	4-(3-Bromo-phenylamino)-quinazoline-6,7-diol		Investigative	[87]
MOA	Inhibitor
External Link	CID: 5328050 TTD: D0J9WO
Compound Name	6,7-dimethoxy-4-(4-phenylbut-1-ynyl)quinazoline		Investigative	[82]
Synonyms	CHEMBL250318; BDBM50222435 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 14 nM
External Link	CID: 44442165 TTD: D0K2VO
Compound Name	4-(2-nitroprop-1-enyl)benzene-1,2-diol		Investigative	[81]
Synonyms	13662-96-9; 1,2-Benzenediol, 4-(2-nitro-1-propenyl)-; AC1MMGH2; Oprea1_551147; CTK0F3796; DTXSID20390758; AKOS017269192 Click to Show/Hide
MOA	Inhibitor
External Link	CID: 3260632 TTD: D0K2YY
Compound Name	EDP-13		Investigative	[9]
Synonyms	Epidermal growth factor receptor antagonist (cancer), BiolineRx/Matrix Pharma Click to Show/Hide
MOA	Antagonist
External Link	TTD: D0K3FG
Compound Name	N4-(3-Bromo-phenyl)-quinazoline-4,7-diamine		Investigative	[83]
Synonyms	CHEMBL420624; 7-amino-4-[(3-bromophenyl)amino]quinazoline; 4-N-(3-bromophenyl)quinazoline-4,7-diamine; 4-Anilinoquinazoline deriv. 48; AC1NS3NB; BDBM3297; SCHEMBL2986298; GHVBIROTJQDRQB-UHFFFAOYSA-N; ZINC3815072; AKOS014671983; 7-Amino-4-(3-bromoanilino)quinazoline; 7-amino-4(3-bromoanilino)-quinazoline; 7-amino-4-(3-bromoanilino)-quinazoline; 169205-81-6; N-(3-Bromophenyl)quinazoline-4,7-diamine; 7-Amino-4-[(3-bromophenyl)aminolquinazoline; FT-0768311; 7-amino-4-[(3-bromophenyl)-amino]quinazoline Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 0.1 nM
External Link	CID: 5328045 TTD: D0K7GD
Compound Name	(S)-benzyl 4-chloro-3-oxobutan-2-ylcarbamate		Investigative	[81]
Synonyms	Z-L-Ala-chloromethylketone; 41036-43-5; Benzyloxycarbonylalanine chloromethyl ketone; Z-Ala-chloromethyl ketone; AC1NUSRJ; PubChem11548; Benzyloxycarbonyl-ala-chloromethyl ketone; CHEMBL483443; SCHEMBL6437509; DTXSID50194009; ZINC34206665; AKOS027382196; FT-0603930; benzyl N-[(2S)-4-chloro-3-oxobutan-2-yl]carbamate; [(S)-1-Methyl-2-oxo-3-chloropropyl]carbamic acid benzyl ester; Carbamic acid, (3-chloro-1-methyl-2-oxopropyl)-, phenylmethyl ester, (S)- Click to Show/Hide
MOA	Inhibitor
External Link	CID: 5491980 TTD: D0KN1L
Compound Name	4-(2-nitrovinyl)benzene-1,2-diol		Investigative	[81]
Synonyms	SL-1; CHEMBL78224; 108074-44-8; SL-1 Pigment; 1,2-Dihydroxy-4-(nitroethenyl)benzene; 4-[(E)-2-nitroethenyl]benzene-1,2-diol; AC1O5R3K; SCHEMBL2052283; SCHEMBL2052285; beta-Nitro-3,4-dihydroxystyrene; LLJASJHXECDHOM-ONEGZZNKSA-N; BDBM50007069; AKOS010878666; 4-(2-Nitro-vinyl)-benzene-1,2-diol; 1,2-Benzenediol, 4-(2-nitroethenyl)-, (E)- Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 8800 nM
External Link	CID: 6439158 TTD: D0L3SN
Compound Name	AG-538		Investigative	[81]
Synonyms	Tyrphostin AG 538; AG 538; NSC676485; (E)-2-(3,4-dihydroxybenzoyl)-3-(3,4-dihydroxyphenyl)prop-2-enenitrile; alpha-Cyano-(3,4-dihydroxy)cinnamoyl-(3& -dihydroxyphenyl)ketone; Tyrphostin deriv. 24; Lopac-T-7822; AC1NS5A3; Lopac0_001261; MLS002153408; CHEMBL56393; SCHEMBL2678764; SCHEMBL2678765; BDBM4293; REGID_for_CID_660907; CHEBI:92138; cid_5328760; REGID_for_CID_5328760; HMS3263N04; HMS2233K10; ZINC3871438; 133550-18-2; Tox21_501261; HSCI1_000189; CCG-205335; NSC-676485; LP01261; NCGC00094499-02 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 370 nM
External Link	CID: 5328760 TTD: D0NH7M
Compound Name	WZ-3146		Investigative	[9]
Synonyms	WZ-4002; WZ-8040; EGFR-T790M kinase inhibitors (lung cancer); EGFR-T790M kinase inhibitors (lung cancer), Gatekeeper Pharmaceuticals Click to Show/Hide
MOA	Inhibitor
External Link	CID: 44607360 TTD: D0NJ3Q
Compound Name	2-methoxy-4-(2-nitrovinyl)phenol		Investigative	[81]
Synonyms	6178-42-3; 2-Methoxy-4-[(E)-2-nitroethenyl]phenol; 1-(4-HYDROXY-3-METHOXYPHENYL)-2-NITROETHENE; (E)-2-methoxy-4-(2-nitrovinyl)phenol; trans-4-Hydroxy-3-methoxy-beta-nitrostyrene; 2-methoxy-4-[(E)-2-nitrovinyl]phenol; CHEMBL309016; 22568-51-0; AF-467/00017042; 2-methoxy-4-(2-nitroethenyl)phenol; 2-Methoxy-4-(2-nitro-vinyl)-phenol; 4-((1E)-2-nitrovinyl)-2-methoxyphenol; 4-{2-nitrovinyl}-2-methoxyphenol; 4-Hydroxy-3-methoxy-beta-nitrostyrene; AC1LCWDN; PubChem19447; AC1Q1WR9; MLS000574924 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 7900 nM
External Link	CID: 638439 TTD: D0O9UR
Compound Name	MG-111		Investigative	[100]
Synonyms	134865-04-6; EGF, Hitachi Click to Show/Hide
MOA	Modulator
External Link	CID: 16143379 TTD: D0P0JW
Compound Name	6,7-dimethoxy-4-(2-phenylethynyl)quinazoline		Investigative	[82]
Synonyms	CHEMBL250315; SCHEMBL6180450; BDBM50222433 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 5600 nM
External Link	CID: 18770812 TTD: D0P2GE
Compound Name	Anti-EGFR humanized mabs		Investigative	[9]
Synonyms	Anti-EGFR humanized mAbs (cancer); Anti-EGFR humanized mAbs (cancer), Xencor; Anti-EGFR humanized monoclonal antibodies (cancer), Xencor Click to Show/Hide
External Link	TTD: D0R2RV
Compound Name	4-biphenyl-2-ylethynyl-6,7-dimethoxy-quinazoline		Investigative	[82]
Synonyms	CHEMBL250924; BDBM50222419 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 26 nM
External Link	CID: 44442180 TTD: D0S9QP
Compound Name	AL-6802		Investigative	[9]
Synonyms	EGFR modulators (cancer), Advenchen/Simcere Click to Show/Hide
MOA	Modulator
External Link	TTD: D0T7OS
Compound Name	BPIQ-I		Investigative	[87]
Synonyms	174709-30-9; N-(3-bromophenyl)-3-methyl-3H-imidazo[4,5-g]quinazolin-8-amine; 8-[(3-Bromophenyl)amino]-3-methyl-3H-imidazo[4,5-g]-quinazoline; Imidazoquinazoline deriv. 12; AC1L1DNH; GTPL5939; CHEMBL174426; BDBM3574; SCHEMBL17931472; CTK8E6742; DTXSID60274366; MolPort-044-561-412; HMS3229C05; ZINC2391775; IN1402; HSCI1_000090; AKOS025394452; CCG-206740; ACM174709309; RT-011807; J-011030; BRD-K72211743-001-01-1 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 0.025 nM
External Link	CID: 2427 TTD: D0U6WB
Compound Name	mabionHER2		Investigative	[9]
Synonyms	Humanized monoclonal antibody (breast cancer), Mabion Click to Show/Hide
External Link	TTD: D0V0JV
Compound Name	4-(2-nitrovinyl)phenol		Investigative	[81]
Synonyms	4-Hydroxy-b-nitrostyrene; (E)-4-(2-nitrovinyl)phenol; 4-hydroxy-beta-nitrostyrene; trans-4-Hydroxy-beta-nitrostyrene; 22568-49-6; Phenol, p-(2-nitrovinyl)-; 4-[(E)-2-Nitroethenyl]phenol; 4-[(E)-2-nitrovinyl]phenol; CHEMBL307481; CTJKRKMPTRJAIT-AATRIKPKSA-N; NSC81594; 1-(4-hydroxyphenyl)-2-nitroethene; 4-(2-(Hydroxy(oxido)amino)vinyl)phenol; 4-(2-Nitro-vinyl)-phenol; NSC30299; AC1LCWDH; 4-Hydroxy--nitrostyrene; 4'-hydroxy-beta-nitrostyrene; Phenol,4-(2-nitroethenyl)- Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 10000 nM
External Link	CID: 638437 TTD: D0W1BE
Compound Name	4-acrylamido-N-(3-bromophenyl)-2-hydroxybenzamide		Investigative	[90]
Synonyms	CHEMBL200958 Click to Show/Hide
MOA	Inhibitor
External Link	CID: 44406548 TTD: D0W2PQ
Compound Name	MDP-01		Investigative	[9]
Synonyms	Peptabody-EGF (anticancer), Med Discovery Click to Show/Hide
MOA	Inhibitor
External Link	TTD: D0WD8R
Compound Name	N4-(3-methylphenyl)-4,6-quinazolinediamine		Investigative	[101]
Synonyms	CHEMBL336113; Anilinoquinazoline, 4a; 6-amino-4-[(3-methylphenyl)amino]quinazoline; SMA52; SCHEMBL159209; ZINC6328; SMA-52; NFBCSWGEYDCCDW-UHFFFAOYSA-N; BDBM50133384; AKOS013914431; N4-m-Tolyl-quinazoline-4,6-diamine; 153436-70-5; 6-amino-4-(3'-methylanilino)quinazoline; 6-amino-4-(3-methylphenylamino)-quinazoline; FT-0765557; 6-amino-4[(3-methylphenyl)amino]quinazoline Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 1000 nM
External Link	CID: 10220590 TTD: D0X4UE
Compound Name	RX-1792		Investigative	[9]
Synonyms	EGF antagonist, Rexahn; RX-0183 Click to Show/Hide
MOA	Antagonist
External Link	TTD: D0Y1LD
Compound Name	(3-Bromo-phenyl)-(5-nitro-quinazolin-4-yl)-amine		Investigative	[83]
Synonyms	N-(3-bromophenyl)-5-nitroquinazolin-4-amine; AC1NS3MQ; BDBM3290; CHEMBL116308; 4-Anilinoquinazoline deriv. 41 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 355 nM
External Link	CID: 5328038 TTD: D0Y2AM
Compound Name	NRC-2694		Investigative	[9]
MOA	Inhibitor
External Link	CID: 16129168 TTD: D0Y6MD
Compound Name	Cochliobolic acid		Investigative	[102]
Synonyms	CHEMBL464721; 185846-15-5; AC1O516J; BDBM50292386; 2-Furancarboxylic acid, tetrahydro-3-hydroxy-5-(17-methyl-13,14-dioxo-1,3,5,7,9,11,15-nonadecaheptaenyl)-, (2alpha,3beta,5alpha(1E,3E,5E,7E,9E,11E,15E))-(partial)-; (2R,3R,5S)-3-hydroxy-5-[(1E,3E,5E,7E,9E,11E,15E)-17-methyl-13,14-dioxononadeca-1,3,5,7,9,11,15-heptaenyl]oxolane-2-carboxylic acid Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 1600 nM
External Link	CID: 6450172 TTD: D0ZT9D
Compound Name	PD-168393		Investigative	[103]
Synonyms	PD168393; 194423-15-9; pd 168393; UNII-3R996Y9T0I; 4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline; n-{4-[(3-bromophenyl)amino]quinazolin-6-yl}prop-2-enamide; N-[4-(3-bromoanilino)quinazolin-6-yl]prop-2-enamide; CHEMBL285063; 3R996Y9T0I; C17H13BrN4O; N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide; 2-Propenamide, N-(4-((3-bromophenyl)amino)-6-quinazolinyl)-; 2-Propenamide, N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-; nchembio866-comp2; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)acrylamide Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 0.08 nM
External Link	CID: 4708 TTD: D01VFR DrugBank: DB07662
Compound Name	N-(4-m-Tolylamino-quinazolin-6-yl)-acrylamide		Investigative	[97]
Synonyms	CHEMBL31815; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl]acrylamide; N-[4-[(3-methyl-phenyl)amino]quinazolin-6-yl)acrylamide; SCHEMBL2991796; AWQLTDUXGVCRBV-UHFFFAOYSA-N; BDBM50077244 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 0.42 nM
External Link	CID: 9995195 TTD: D01WYI
Compound Name	4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinazoline		Investigative	[104]
Synonyms	CHEMBL98798 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 70 nM
External Link	CID: 44331231 TTD: D03HLH
Compound Name	4-(3-Bromo-phenoxy)-6,7-dimethoxy-quinoline		Investigative	[104]
Synonyms	CHEMBL101581 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 2500 nM
External Link	CID: 44331083 TTD: D05QMN
Compound Name	YH013		Investigative	[105]
External Link	TTD: D0AM9O
Compound Name	LAVENDUSTIN A		Investigative	[106]
Synonyms	125697-92-9; RG14355; UNII-3Y0G32G2RV; CHEMBL103552; 3Y0G32G2RV; C21H19NO6; Lavendustin A, from Streptomyces griseolavendus; Benzoic acid,5-[[(2,5-dihydroxyphenyl)methyl][(2-hydroxyphenyl)methyl]amino]-2-hydroxy-; RG 14355; 5-(((2,5-Dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxybenzoic acid; Benzoic acid, 5-(((2,5-dihydroxyphenyl)methyl)((2-hydroxyphenyl)methyl)amino)-2-hydroxy-; 5-Amino-((N-2,5-dihydroxybenzyl)-N -2-hydroxybenzyl)salicylic acid Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 0.004 ug.mL-1
External Link	CID: 3894 TTD: D0D9TU
Compound Name	PF 5208766		Investigative	[107]
Synonyms	WAY-178357 Click to Show/Hide
MOA	Modulator
External Link	TTD: D0J2CP
Compound Name	6-chloro-N-(3-chlorophenyl)quinazolin-4-amine		Investigative	[108]
Synonyms	4-Anilidoquinazoline deriv. 12a; AC1NS5EY; SCHEMBL4355658; BDBM4397 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 2700 nM
External Link	CID: 5328819 TTD: D0J5SK
Compound Name	N-(4-(phenylamino)quinazolin-6-yl)acrylamide		Investigative	[103]
Synonyms	CHEMBL1221699; N-[4-(phenylamino)quinazolin-6-yl]prop-2-enamide; nchembio866-comp4; SCHEMBL614989; BDBM50324687; DB08462; N-(4-Anilinoquinazoline-6-yl)acrylamide Click to Show/Hide
MOA	Inhibitor
Activity	IC50 < 1 nM
External Link	CID: 10401956 TTD: D0N8TQ DrugBank: DB08462
Compound Name	AG-213		Investigative	[99]
MOA	Inhibitor
Activity	Ki = 850 nM
External Link	CID: 667601 TTD: D0Q3GG
Compound Name	SYM-011		Investigative	[9]
Synonyms	Dimercept; Hermodulins; Herstatin; RB-200; RBLX-200; RBLX-242; RBLX-242h; RBLX-642h Click to Show/Hide
MOA	Modulator
External Link	TTD: D0Q8GX
Compound Name	10-hydroxy-18-methoxybetaenone		Investigative	[109]
Synonyms	CHEMBL498247; BDBM50269144 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 10500 nM
External Link	CID: 10644450 TTD: D0W6CE
Compound Name	4557W		Investigative	[110]
Synonyms	EGFR/ErbB-2 Inhibitor; 179248-61-4; 4-(4-Benzyloxyanilino)-6,7-dimethoxyquinazoline; SCHEMBL242224; GTPL5964; CHEMBL563845; CTK8E8822; DTXSID40431718; MolPort-018-661-221; HMS3229C21; ZINC1485577; IN1350; HSCI1_000238; AKOS002350936; CCG-206748; RT-012453; J-011438; BRD-K76819286-001-01-0; N-[4-(Benzyloxy)phenyl]-6,7-dimethoxyquinazoline-4-amine; N-[4-(benzyloxy)phenyl]-6,7-dimethoxyquinazolin-4-amine Click to Show/Hide
MOA	Inhibitor
External Link	CID: 9843206 TTD: D0X4OU
Compound Name	Tyrphostin ag-1478		Investigative	[96]
Synonyms	AG-1478; 153436-53-4; Tyrphostin AG 1478; N-(3-chlorophenyl)-6,7-dimethoxyquinazolin-4-amine; 175178-82-2; 4-(3-Chloroanilino)-6,7-dimethoxyquinazoline; AG 1478; AG1478; TYRPHOSTIN; 4-Quinazolinamine, N-(3-chlorophenyl)-6,7-dimethoxy-; UNII-SUH0SEZ9HY; SUH0SEZ9HY; AG-1478 hydrochloride; AG-1478 (Tyrphostin AG-1478); CHEMBL7917; CHEBI:75404; N-(3-Chlorophenyl)-6,7-dimethoxy-4-quinazolinamine; NSC-693255; AK-63142; N-(3-chlorophenyl)-6,7-dimethoxy-quinazolin-4-amine; BRD6408; BRD-6408; SR-01000076156; NSC693255 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 120 nM
External Link	CID: 2051 TTD: D0ZH1U
Compound Name	CL-387785		Investigative	[91]
Synonyms	194423-06-8; EKI-785; CL-387785 (EKI-785); CL-387,785; UNII-B4W27J1Z8B; CL-387785(EKI785; WAY-EKI 785); EKB-785; CHEMBL91867; B4W27J1Z8B; N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-butynamide; N-(4-((3-bromophenyl)amino)quinazolin-6-yl)but-2-ynamide; CHEBI:90180; C18H13BrN4O; N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}but-2-ynamide; N-[4-[(3-Bromophenyl)amino]quinazolin-6-yl]but-2-ynamide; N-[4-[(3-bromophenyl)amino]-6-quinazolinyl)-2-butynamide; N-{4-[(3-bromophenyl)amino]-6-quinazolinyl}-2-butynamide Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 0.37 nM
External Link	CID: 2776 TTD: D00TZD
Compound Name	HDS-029		Investigative	[111]
Synonyms	HDS 029 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 0.3 nM
External Link	CID: 11566580 TTD: D05FFT
Compound Name	WHI-P154		Investigative	[112]
MOA	Inhibitor
External Link	CID: 3795 TTD: D0E5IP
Compound Name	PMID24915291C38		Investigative	[113]
Synonyms	GTPL8145; PLS-123; BDBM50020476; 1431727-04-6 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 7 nM
External Link	CID: 71556703 TTD: D06BJG
Compound Name	HKI-9924129		Investigative	[114]
MOA	Inhibitor
Activity	IC50 = 390 nM
External Link	CID: 5311104 TTD: D0D5EW
Compound Name	PD-0173956		Investigative	[114]
Synonyms	UNII-YR2DP5GJ1Y; YR2DP5GJ1Y; PD173956; PD-173956; AC1NS9BQ; 305820-76-2; SCHEMBL1334768; BDBM6569; CHEMBL574059; Pyrido(2,3-d)pyrimidin-7(8H)-one, 6-(2,6-dichlorophenyl)-2-((4-fluorophenyl)amino)-8-methyl-; 6-(2,6-dichlorophenyl)-2-(4-fluoroanilino)-8-methylpyrido[2,3-d]pyrimidin-7-one; 6-(2,6-dichlorophenyl)-2-[(4-fluorophenyl)amino]-8-methyl-7H,8H-pyrido[2,3-d]pyrimidin-7-one Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 380 nM
External Link	CID: 5330524 TTD: D0GW4Q
Compound Name	PD-0166326		Investigative	[114]
Synonyms	PD-166326 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 90 nM
External Link	CID: 447700 TTD: D0P3JW DrugBank: DB08339
Compound Name	PP121		Investigative	[115]
Synonyms	PP-121; PP 121 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 260 nM
External Link	CID: 24905142 TTD: D03EHM DrugBank: DB08052
Compound Name	3-(indole-3-yl)-4-phenyl-1H-pyrrole-2,5-dione		Investigative	[116]
Synonyms	CHEMBL380598; SCHEMBL3148490; HVQJGNALTWNDMX-UHFFFAOYSA-N; BDBM50375058; 2-(1H-Indole-3-yl)-3-phenylmaleimide Click to Show/Hide
MOA	Inhibitor
External Link	CID: 15422868 TTD: D06AOY
Compound Name	Ro-4396686		Investigative	[117]
Synonyms	SCHEMBL5809947; CHEMBL606964 Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 545 nM
External Link	CID: 11396738 TTD: D09XIL
Compound Name	3,4-di-(4-methoxyphenyl)-1H-pyrrole-2,5-dione		Investigative	[116]
Synonyms	1H-Pyrrole-2,5-dione, 3,4-bis(4-methoxyphenyl)-; 108774-82-9; ACMC-20mbs9; CHEMBL381099; CTK0G2626; DTXSID90449388 Click to Show/Hide
MOA	Inhibitor
External Link	CID: 10946795 TTD: D00NYT
Compound Name	3,4-diphenyl-1H-pyrrole-2,5-dione		Investigative	[116]
Synonyms	2,3-diphenylmaleimide; 1H-Pyrrole-2,5-dione, 3,4-diphenyl-; 31295-36-0; AC1MBL6S; SCHEMBL114611; CHEMBL201949; CTK1B9880; 3,4-diphenylpyrrole-2,5-dione; DTXSID70372903; ZINC3847556 Click to Show/Hide
MOA	Inhibitor
External Link	CID: 2752461 TTD: D0C3WY
Compound Name	3-(4-methoxyphenyl)-4-phenyl-1H-pyrrole-2,5-dione		Investigative	[116]
Synonyms	CHEMBL372076; SCHEMBL3822337 Click to Show/Hide
MOA	Inhibitor
External Link	CID: 11572699 TTD: D0EK0G
Compound Name	Osimertinib		Approved	[10]
Synonyms	Tagrisso Click to Show/Hide
MOA	Inhibitor
Activity	IC50 = 0.421 nM
External Link	CID: 71496458 TTD: D0O8GK DrugBank: DB09330
Compound Name	PMID27774824-Compound-Figure9Example2down		Patented	[118]
External Link	TTD: D01DBB
Compound Name	Mobocertinib		Approved	[118]
Synonyms	1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate Click to Show/Hide
External Link	CID: 118607832 TTD: DI4HA7
Compound Name	DZD9008		Phase 1/2	[118]
External Link	TTD: DM8Y2N
Compound Name	AC0010		Phase 3	[118]
Synonyms	Avitinib; 1557267-42-1; N-(3-((2-((3-Fluoro-4-(4-methylpiperazin-1-yl)phenyl)amino)-7H-pyrrolo[2,3-d]pyrimidin-4-yl)oxy)phenyl)acrylamide; Avitinib free base; SCHEMBL15453394; KS-00000TON; EX-A783; MolPort-042-663-560; Avitinib(AC0010/AC0010MA); ZINC142081723; AKOS030632728; CS-W008904; N-(3-{2-[3-Fluoro-4-(4-methyl-piperazin-1-yl)-phenylamino]-7H-pyrrolo[2,3-d]pyrimidin-4-yloxy}-phenyl)-acrylamide; DS-19269; AK543905; 2-Propenamide, N-[3-[[2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-7H-pyrrolo[2,3-d]pyrimidin-4- Click to Show/Hide
External Link	CID: 72734520 TTD: D0FV3K DrugBank: DB15327
Compound Name	EGFR antisense DNA		Phase 1/2	[118]
Synonyms	Antisense therapy, UPCI; EGFR antisense DNA, University of Pittsburgh Click to Show/Hide
External Link	TTD: D06VFF
Compound Name	CK-101		Phase 1/2	[118]
Synonyms	IDRGFNPZDVBSSE-UHFFFAOYSA-N; 1660963-42-7; RX-518; N-(3-(2-((2,3-Difluoro-4-(4-(2-hydroxyethyl)piperazin-1-yl)phenyl)amino)quinazolin-8-yl)phenyl)acrylamide; EGFR-IN-3; UNII-708TLB8J3Y; 708TLB8J3Y; AK543910; N-[3-[2-[[2,3-difluoro-4-[4-(2-hydroxyethyl)piperazin-1-yl]phenyl]amino]quinazolin-8-yl]phenyl]acrylamide; GTPL9863; SCHEMBL16514522; KS-00000TOQ; MolPort-042-663-562; RX518; CK101; EX-A1142; BCP19075; RX 518; ZINC514250913; AKOS030632731; DS-19272; HY-19815; CS-0016788; Example 153 [US20170050936A1]; J-690231; 2-Propena Click to Show/Hide
External Link	CID: 117909640 TTD: D09BZS
Compound Name	Pyrotinib		Phase 1	[118]
Synonyms	UNII-CJN36EQM0H; SHR-1258; CJN36EQM0H; SHR1258; 1269662-73-8; SCHEMBL9948753; GTPL9662; SADXACCFNXBCFY-IYNHSRRRSA-N; BDBM139991; AKOS032946680; CS-7940; compound 12 [PMID: 28115222]; 2-Propenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-3-((2R)-1-methyl-2-pyrrolidinyl)-, (2E)-; HY-104065; US8901140, 5; (E)-N-[4-[[3-chloro-4-(2-pyridylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolyl]-3-[(2R)-1-methylpyrrolidin-2-yl]prop-2-enamide; (E)-N-[4-[3-chloro-4-(pyridin-2-ylmetho Click to Show/Hide
External Link	CID: 51039030 TTD: D0M8YM DrugBank: DB14993
Compound Name	Anti-EGFRvIII CAR transduced PBL		Phase 1/2	[118]
External Link	TTD: D08RJY
Compound Name	EGFRvIII CAR		Phase 1/2	[118]
External Link	TTD: D0LU4N
Compound Name	Anti-EGFR V III CAR-T cells		Phase 1/2	[118]
External Link	TTD: D0Q4EJ
Compound Name	EGFRvIII CAR T cells		Phase 1	[118]
External Link	TTD: D01LWE
Compound Name	CAR-T cells targeting EGFRviii		Phase 1	[118]
External Link	TTD: D03CMZ
Compound Name	Anti-EGFRvIII CAR T cells		Phase 1	[118]
External Link	TTD: D09OSC
Compound Name	CART-EGFRvIII T cells		Phase 1	[118]
External Link	TTD: D0B5PV
Compound Name	EGFRvIII-CARs		Phase 1	[118]
External Link	TTD: D0PT2M
Compound Name	CAR-T Cells targeting EGFRvIII		Phase 1	[118]
External Link	TTD: D0ZQ6N
Compound Name	RG6156		Phase 1	[118]
External Link	TTD: DF8X5N
Compound Name	AMG 596		Phase 1	[118]
External Link	TTD: DOJ6E8
Compound Name	D2C7		Phase 1	[66]
External Link	TTD: DR4ND6
2C25: Lung cancer		52 Compound(s) Regulating the Disease	Click to Show/Hide the Full List
Compound Name	Adagrasib		Approved	[119]
Synonyms	2326521-71-3; MRTX-849; UNII-8EOO6HQF8Y; 8EOO6HQF8Y; 2-((S)-4-(7-(8-Chloronaphthalen-1-yl)-2-(((S)-1-methylpyrrolidin-2-yl)methoxy)-5,6,7,8-tetrahydropyrido[3,4-d]pyrimidin-4-yl)-1-(2-fluoroacryloyl)piperazin-2-yl)acetonitrile; CHEMBL4594350; SCHEMBL20974691; GTPL10888; Kras G12C inhibitor MRTX849; BCP31538; EX-A3258; MRTX 849; MFCD32263433; s8884; compound 20 [PMID: 32250617]; BS-16211; HY-130149; CS-0105265; 2-Piperazineacetonitrile, 4-(7-(8-chloro-1-naphthalenyl)-5,6,7,8-tetrahydro-2-(((2S)-1-methyl-2-pyrrolidinyl)methoxy)pyrido(3,4-d)pyrimidin-4-yl)-1-(2-fluoro-1-oxo-2-propen-1-yl)-, (2S)- Click to Show/Hide
External Link	CID: 138611145 TTD: DUQV41
Compound Name	Amivantamab		Approved	[120]
External Link	TTD: DQ5X1Z
Compound Name	Mobocertinib		Approved	[121]
Synonyms	1847461-43-1; TAK-788; TAK788; AP32788; UNII-39HBQ4A67L; 39HBQ4A67L; propan-2-yl 2-[4-{[2-(dimethylamino)ethyl](methyl)amino}-2-methoxy-5-(prop-2-enamido)anilino]-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Mobocertinib [INN]; Mobocertinib [USAN]; AP-32788; Mobocertinib (TAK788); Mobocertinib(TAK-788); SCHEMBL17373133; GTPL10468; BDBM368374; BCP31045; EX-A3392; US10227342, Example 10; MFCD32669806; NSC825519; s6813; TAK-788;AP32788; WHO 11183; NSC-825519; example 94 [WO2015195228A1]; HY-135815; CS-0114256; TAK-788;TAK 788; AP 32788; 5-Pyrimidinecarboxylic acid, 2-((4-((2-(dimethylamino)ethyl)methylamino)-2-methoxy-5-((1-oxo-2-propen-1-yl)amino)phenyl)amino)-4-(1-methyl-1H-indol-3-yl)-, 1-methylethyl ester; C(C=C)(=O)NC=1C(=CC(=C(C=1)NC1=NC=C(C(=N1)C1=CN(C2=CC=CC=C12)C)C(=O)OC(C)C)OC)N(C)CCN(C)C; Isopropyl 2-((5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenyl)amino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Isopropyl 2-(5-acrylamido-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyphenylamino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; Propan-2-yl 2-(5-(acryloylamino)-4-((2-(dimethylamino)ethyl)(methyl)amino)-2-methoxyanilino)-4-(1-methyl-1H-indol-3-yl)pyrimidine-5-carboxylate; propan-2-yl 2-[4-[2-(dimethylamino)ethyl-methylamino]-2-methoxy-5-(prop-2-enoylamino)anilino]-4-(1-methylindol-3-yl)pyrimidine-5-carboxylate Click to Show/Hide
External Link	CID: 118607832 TTD: DI4HA7
Compound Name	Sugemalimab		Approved in China	[122]
External Link	TTD: DDZ48Y
Compound Name	Sacituzumab govitecan		Approved	[123]
Synonyms	1491917-83-9; 1535963-91-7; 1796566-95-4; CYSTEINYL CL2A-SN-38; DA64T2C2IO; DTXSID401335985; EX-A4354; F82944; GOVITECAN CYSTEINYL CONJUGATE; hRS 7SN38; hRS7-SN38; IMMU 132; IMMU-132; M9BYU8XDQ6; Sacituzumab govitecan; Sacituzumab govitecan [USAN]; sacituzumab-govitecan; Satralizumab linker; SN-38 CYSTEINYL CONJUGATE; UNII-M9BYU8XDQ6 Click to Show/Hide
External Link	CID: 91668186 TTD: D8LAE2
Compound Name	Atezolizumab		Approved	[124]
External Link	TTD: D0YM2K
Compound Name	Tepotinib		Approved	[125]
Synonyms	1100598-32-0; EMD 1214063; UNII-1IJV77EI07; Tepotinib (EMD 1214063); EMD1214063; 1IJV77EI07; MSC-2156119J; Benzonitrile, 3-[1,6-dihydro-1-[[3-[5-[(1-methyl-4-piperidinyl)methoxy]-2-pyrimidinyl]phenyl]methyl]-6-oxo-3-pyridazinyl]-; C29H28N6O2; Tepotinib [INN]; Benzonitrile, 3-[1,6-Dihydro-1-[[3-[5-[(1-Methyl-4-Piperidinyl)Methoxy]-2-PyriMidinyl]Phenyl]Methyl]-6-Oxo-3-Pyridazinyl]; Benzonitrile, 3-(1,6-dihydro-1-((3-(5-((1-methyl-4-piperidinyl)methoxy)-2-pyrimidinyl)phenyl)methyl)-6-oxo Click to Show/Hide
External Link	CID: 25171648 TTD: D0R8QG DrugBank: DB15133
Compound Name	Sotorasib		Approved	[126]
Synonyms	AMG-510; AMG510; AMG-510 racemate; 2252403-56-6; AMG 510; Kras G12C inhibitor 9; 2296729-00-3; UNII-2B2VM6UC8G; 2B2VM6UC8G; CHEMBL4535757; 2296729-00-3 (racemate); 4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-[(2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl]pyrido[2,3-d]pyrimidin-2-one; Sotorasib [INN]; 6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-propan-2-ylpyridin-3-yl)-4-((2S)-2-methyl-4-prop-2-enoylpiperazin-1-yl)pyrido(2,3-d)pyrimidin-2-one; AMG510 racemate; Sotorasib [USAN]; AMG-510(racemate); Kras mutant-targeting AMG 510; SCHEMBL20560375; GTPL10678; AMG 510 pound>>AMG-510; AMY16918; BCP30452; BCP33368; EX-A3538; BDBM50514402; NSC818433; s8830; WHO 11370; DB15569; NSC-818433; BS-16684; HY-114277; CS-0081316; compound (R)-38 [PMID: 31820981]; (1m)-6-Fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(propan-2-yl)pyridin-3-yl)-4-((2S)-2-methyl-4-(prop-2-enoyl)piperazin-1-yl)pyrido(2,3-d)pyrimidin-2(1H)-one; (1S)-4-((S)-4-Acryloyl-2-methylpiperazin-1-yl)-6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(2-isopropyl-4-methylpyridin-3-yl)pyrido[2,3-d]pyrimidin-2(1H)-one; 2296729-66-1; Pyrido(2,3-d)pyrimidin-2(1H)-one, 6-fluoro-7-(2-fluoro-6-hydroxyphenyl)-1-(4-methyl-2-(1-methylethyl)-3-pyridinyl)-4-((2S)-2-methyl-4-(1-oxo-2-propen-1-yl)-1-piperazinyl)- Click to Show/Hide
External Link	CID: 137278711 TTD: D0R7LD DrugBank: DB15569
Compound Name	Entrectinib		Approved	[127]
Synonyms	1108743-60-7; RXDX-101; UNII-L5ORF0AN1I; Entrectinib (RXDX-101); L5ORF0AN1I; Benzamide, N-[5-[(3,5-difluorophenyl)methyl]-1H-indazol-3-yl]-4-(4-methyl-1-piperazinyl)-2-[(tetrahydro-2H-pyran-4-yl)amino]-; Benzamide, N-(5-((3,5-difluorophenyl)methyl)-1H-indazol-3-yl)-4-(4-methyl-1-piperazinyl)-2-((tetrahydro-2H-pyran-4-yl)amino)-; Entrectinib [USAN:INN]; YMX; Kinome_2659; Entrectinib(rxdx-101); Entrectinib (USAN/INN); SCHEMBL3512601; GTPL8290; CHEMBL1983268; KS-00000TSK Click to Show/Hide
External Link	CID: 25141092 TTD: D0O0LS DrugBank: DB11986
Compound Name	Repotrectinib		Approved	[128]
Synonyms	FIKPXCOQUIZNHB-RRKGBCIJSA-N; SCHEMBL20438940; TPX 0005; BCP19778 Click to Show/Hide
External Link	CID: 135565923 TTD: D05NFR
Compound Name	MYL-1402O		Phase 3	[129]
Synonyms	bevacizumab biosimilar Click to Show/Hide
External Link	TTD: DYH3Q6
Compound Name	AB154		Phase 3	[130]
Synonyms	Domvanalimab Click to Show/Hide
External Link	TTD: DT1FS0
Compound Name	Datopotamab deruxtecan		Phase 3	[131]
External Link	TTD: DP41HV
Compound Name	CS1001		Phase 3	[132]
External Link	TTD: D3MP1S
Compound Name	JDQ443		Phase 3	[133]
Synonyms	(S)-JDQ-443; 1-(6-((4S)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl)-2-azaspiro[3.3]heptan-2-yl)prop-2-en-1-one; 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-inda zol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]- 2-Propen-1-one; 1-[6-[(4R)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-2-propen-1-one; 1-[6-[4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methylindazol-5-yl)pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl]prop-2-en-1-one; 1-{6-[(4M)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5- methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2- azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 1-{6-[(4M)-4-(5-Chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]heptan-2-yl}prop-2-en-1-one; 2653994-08-0; 2653994-10-4; 2-Propen-1-one, 1-[6-[(4R)-4-(5-chloro-6-methyl-1H-indazol-4-yl)-5-methyl-3-(1-methyl-1H-indazol-5-yl)-1H-pyrazol-1-yl]-2-azaspiro[3.3]hept-2-yl]-; AKOS040757949; AT36708; BDBM50579985; CHEMBL5077861; compound 5 [PMID: 35404998]; CS-0226220; CS-0311034; EX-A5693; example 1a [WO2021120890A1]; GLXC-25533; GTPL11715; HY-139612A; JDQ 443; JDQ 443 [WHO-DD]; JDQ443; JDQ-443; MS-29737; NSC846146; NSC-846146; NVP-JDQ443; NVP-JDQ-443; Opnurasib; opnurasib [INN]; -PROPEN-1-ONE, 1-(6-((4R)-4-(5-CHLORO-6-METHYL-1H-INDAZOL-4-YL)-5-METHYL-3-(1-METHYL-1H-INDAZOL-5-YL)-1H-PYRAZOL-1-YL)-2-AZASPIRO(3.3)HEPT-2-YL)-; Q3W0H3V1LQ; SCHEMBL23533580 Click to Show/Hide
External Link	CID: 156501355 TTD: D37IQM
Compound Name	TRS003		Phase 3	[134]
External Link	TTD: D2KVG4
Compound Name	Tusamitamab ravtansine		Phase 3	[135]
Synonyms	SAR408701 Click to Show/Hide
External Link	TTD: D2D6NJ
Compound Name	RG6058		Phase 3	[136]
Synonyms	Tiragolumab Click to Show/Hide
External Link	TTD: D0L4VD
Compound Name	GSK4069889		Phase 2	[137]
Synonyms	TSR-022 Click to Show/Hide
External Link	TTD: DZW53X
Compound Name	APL-101		Phase 2	[138]
Synonyms	Bozitinib; PLB-1001; 1440964-89-5; Vebreltinib; Vebreltinib [USAN]; UNII-2WZP8A9VFN; 2WZP8A9VFN; Bozitinib (PLB-1001); SCHEMBL15594471; BDBM107096; CBI-3103; s6762; WHO 11677; HY-125017; CS-0088607; US9695175, 44; 1,2,4-Triazolo(4,3-b)pyridazine, 6-(1-cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6- fluoro-2-methyl-2H-indazol-5-yl)methyl)-; 6-(1-Cyclopropyl-1H-pyrazol-4-yl)-3-(difluoro(6-fluoro-2-methyl-2H-indazol-5- yl)methyl)-1,2,4-triazolo(4,3-b)pyridazine Click to Show/Hide
External Link	CID: 72202701 TTD: DV3Y7F
Compound Name	SGN-LIV1A		Phase 2	[139]
Synonyms	Ladiratuzumab Vedotin Click to Show/Hide
External Link	TTD: DS6B1L
Compound Name	BNT116		Phase 2	[140]
External Link	TTD: DR39GZ
Compound Name	AZD7789		Phase 2	[141]
External Link	TTD: DNI7E3
Compound Name	L-DOS47		Phase 1/2	[142]
External Link	TTD: DN3Z5D
Compound Name	NC318		Phase 2	[143]
External Link	TTD: D9UZ5Q
Compound Name	Vorolanib		Phase 2	[144]
Synonyms	UNII-YP8G3I74EL; YP8G3I74EL; 1013920-15-4; (S,Z)-N-(1-(Dimethylcarbamoyl)pyrrolidin-3-yl)-5-((5-fluoro-2-oxoindolin-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; Vorolanib [INN]; SCHEMBL2439528; CHEMBL4297587; N-((3S)-1-(dimethylcarbamoyl)pyrrolidin-3-yl)-5-((Z)-(5-fluoro-2-oxo-1H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-carboxamide; s6843; DB15247; HY-109019; CS-0030517; Q27294638; 1H-Pyrrole-3-carboxamide, N-((3S)-1-((dimethylamino)carbonyl)-3-pyrrolidinyl)-5-((Z)-(5-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl- Click to Show/Hide
External Link	CID: 59215954 TTD: D8AG3S DrugBank: DB15247
Compound Name	Xofigo		Phase 2	[145]
External Link	TTD: D6B7FP
Compound Name	Bintrafusp alfa		Phase 2	[146]
External Link	TTD: D5J3BL
Compound Name	Voyager-V1		Phase 2	[147]
Synonyms	VSV-IFNBeta-NIS Click to Show/Hide
External Link	TTD: D4AGB6
Compound Name	AB-106		Phase 2	[148]
Synonyms	DS6051b; GTPL11198; AB106 Click to Show/Hide
External Link	CID: 154699459 TTD: D2KV8B
Compound Name	RO-5126766		Phase 2	[149]
Synonyms	VS-6766; CH-5126766; Dual Raf/MEK protein kinase inhibitor (cancer), Roche Click to Show/Hide
External Link	CID: 16719221 TTD: D0M6BD DrugBank: DB15254
Compound Name	TC-210		Phase 1/2	[150]
External Link	TTD: DX6O9V
Compound Name	EMB-01		Phase 1/2	[151]
External Link	TTD: DWQ6J1
Compound Name	NM21-1480		Phase 1/2	[152]
External Link	TTD: DUVH60
Compound Name	MRx0518		Phase 1/2	[153]
External Link	TTD: DP4J2K
Compound Name	DZD9008		Phase 1/2	[154]
External Link	TTD: DM8Y2N
Compound Name	BGB-A425		Phase 1/2	[155]
External Link	TTD: D7UIZ1
Compound Name	Rilvegostomig		Phase 1/2	[156]
Synonyms	AZD2936 Click to Show/Hide
External Link	TTD: D4RMC9
Compound Name	IK-007		Phase 1/2	[157]
Synonyms	grapiprant Click to Show/Hide
External Link	TTD: D1KES8
Compound Name	IBI318		Phase 1	[158]
External Link	TTD: DX30BA
Compound Name	GEN-011		Phase 1	[159]
External Link	TTD: DR1YQ7
Compound Name	ENV-105		Phase 1	[160]
Synonyms	Carotuximab Click to Show/Hide
External Link	TTD: DQ8K3R
Compound Name	AMG 160		Phase 1	[161]
External Link	TTD: DOY4E6
Compound Name	ADP-A2M10		Phase 1	[162]
External Link	TTD: DM38KC
Compound Name	MEDI5752		Phase 1	[163]
External Link	TTD: D7L1MP
Compound Name	PF-07104091		Phase 1	[164]
External Link	TTD: D5TH2B
Compound Name	PF-06936308		Phase 1	[165]
External Link	TTD: D2LUK7
Compound Name	GEM3PSCA		Phase 1	[166]
External Link	TTD: D1L7DE
Compound Name	PF-07257876		Phase 1	[167]
External Link	TTD: D1A7OP
Compound Name	Cosibelimab		Phase 1	[168]
Synonyms	CK-301/TG-1501 Click to Show/Hide
External Link	TTD: D17URP
Compound Name	Gemcitabine		Approved	[169]
External Link	CID: 60750 TTD: D0AJ3K DrugBank: DB00441
Compound Name	SMI-4a		Investigative	[170]
Synonyms	438190-29-5; SMI 4a; TCS PIM-1 4a; (Z)-SMI-4a; (Z)-5-(3-(trifluoromethyl)benzylidene)thiazolidine-2,4-dione; (5Z)-5-[3-(trifluoromethyl)benzylidene]-1,3-thiazolidine-2,4-dione; CHEMBL183906; (5Z)-5-[[3-(TRIFLUOROMETHYL)PHENYL]METHYLENE]-2,4-THIAZOLIDINEDIONE; (5Z)-5-[[3-(trifluoromethyl)phenyl]methylidene]-1,3-thiazolidine-2,4-dione; 327033-36-3; C11H6F3NO2S; (Z)-5-(3-(Trifluoromethyl)benzylidene)-thiazolidine-2,4-dione; (5Z)-5-{[3-(trifluoromethyl)phenyl]methylidene}-1,3-thiazolidine-2,4-dione; Pim inhibitor 4a; 3vc4; SMI-4q; TCS PIM-1-4a; 5-(3-(Trifluoromethyl)benzylidene)thiazolidine-2,4-dione; 5-[3-(Trifluoromethyl)benzylidene]thiazolidine-2,4-dione; cc-717; thiazolidine-2,4-dione, 4a; SCHEMBL2541382; SCHEMBL2541388; BDBM26626; AOB6260; EX-A111; SYN1113; BDBM138364; HMS3229J21; 2720AH; HY-16576A; MFCD01152003; s8005; ZINC12576047; AKOS001314163; SMI-4a, >=98% (HPLC); CCG-265027; NCGC00345836-02; NCGC00345836-14; AC-32861; HY-15474; AB0165836; EC-000.2291; J3.561.866J; A11945; W-5256; US8877795, 12; Q27451064; 5-[[3-(trifluoromethyl)phenyl]methylene]-2,4-thiazolidinedione Click to Show/Hide
External Link	CID: 1361334 TTD: DAJ3D2

References

Ref 1	MiR-33a suppresses proliferation of NSCLC cells via targeting METTL3 mRNA. Biochem Biophys Res Commun. 2017 Jan 22;482(4):582-589. doi: 10.1016/j.bbrc.2016.11.077. Epub 2016 Nov 14.
Ref 2	Rindopepimut, a 14-mer injectable peptide vaccine against EGFRvIII for the potential treatment of glioblastoma multiforme. Curr Opin Mol Ther. 2010 Dec;12(6):741-54.
Ref 3	Emerging drugs for diabetic foot ulcers. Expert Opin Emerg Drugs. 2006 Nov;11(4):709-24. doi: 10.1517/14728214.11.4.709.
Ref 4	Quantitative prediction of fold resistance for inhibitors of EGFR. Biochemistry. 2009 Sep 8;48(35):8435-48. doi: 10.1021/bi900729a.
Ref 5	Gefitinib ('Iressa', ZD1839) and new epidermal growth factor receptor inhibitors. Br J Cancer. 2004 Feb 9;90(3):566-72.
Ref 6	Integration of panitumumab into the treatment of colorectal cancer. Crit Rev Oncol Hematol. 2010 Apr;74(1):16-26. doi: 10.1016/j.critrevonc.2009.06.005. Epub 2009 Jul 17.
Ref 7	Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther. 2002 May;1(7):507-14.
Ref 8	Boehringer Ingelheim. Product Development Pipeline. June 2 2009.
Ref 9	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1797).
Ref 10	AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov. 2014 Sep;4(9):1046-61. doi: 10.1158/2159-8290.CD-14-0337. Epub 2014 Jun 3.
Ref 11	2017 FDA drug approvals. Nat Rev Drug Discov. 2018 Feb;17(2):81-85. doi: 10.1038/nrd.2018.4. Epub 2018 Jan 19.
Ref 12	Antitumor Activity of Amivantamab (JNJ-61186372), an EGFR-MET Bispecific Antibody, in Diverse Models of EGFR Exon 20 Insertion-Driven NSCLC. Cancer Discov. 2020 Aug;10(8):1194-1209. doi: 10.1158/2159-8290.CD-20-0116. Epub 2020 May 15.
Ref 13	Synthesis and Src kinase inhibitory activity of a series of 4-[(2,4-dichloro-5-methoxyphenyl)amino]-7-furyl-3-quinolinecarbonitriles. J Med Chem. 2006 Dec 28;49(26):7868-76. doi: 10.1021/jm061031t.
Ref 14	Triple negative breast cancer--current status and prospective targeted treatment based on HER1 (EGFR), TOP2A and C-MYC gene assessment. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. 2009 Mar;153(1):13-7. doi: 10.5507/bp.2009.002.
Ref 15	Clinical pipeline report, company report or official report of GlaxoSmithKline (2009).
Ref 16	A comparison of physicochemical property profiles of marketed oral drugs and orally bioavailable anti-cancer protein kinase inhibitors in clinical development. Curr Top Med Chem. 2007;7(14):1408-22.
Ref 17	Nasopharyngeal carcinoma: Current treatment options and future directions. J Nasopharyng Carcinoma, 2014, 1(16): e16.
Ref 18	Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer. 2011 Aug;73(2):195-202. doi: 10.1016/j.lungcan.2010.11.007. Epub 2010 Dec 8.
Ref 19	Sym004, a novel EGFR antibody mixture, can overcome acquired resistance to cetuximab. Neoplasia. 2013 Oct;15(10):1196-206. doi: 10.1593/neo.131584.
Ref 20	Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov. 2013 Dec;3(12):1404-15.
Ref 21	Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med. 2015 Apr 30;372(18):1700-9. doi: 10.1056/NEJMoa1413654.
Ref 22	Safety, Efficacy, and Pharmacokinetics of Almonertinib (HS-10296) in Pretreated Patients With EGFR-Mutated Advanced NSCLC: A Multicenter, Open-label, Phase 1 Trial. J Thorac Oncol. 2020 Dec;15(12):1907-1918. doi: 10.1016/j.jtho.2020.09.001. Epub 2020 Sep 9.
Ref 23	ClinicalTrials.gov (NCT04305795) An Open-label Study Using ASP-1929 Photoimmunotherapy in Combination With Anti-PD1 Therapy in EGFR Expressing Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 24	Clinical pipeline report, company report or official report of Klus Pharma
Ref 25	Clinical pipeline report, company report or official report of Roche (2009).
Ref 26	Dual irreversible kinase inhibitors: quinazoline-based inhibitors incorporating two independent reactive centers with each targeting different cysteine residues in the kinase domains of EGFR and VEGFR-2. Bioorg Med Chem. 2007 Jun 1;15(11):3635-48. doi: 10.1016/j.bmc.2007.03.055. Epub 2007 Mar 23.
Ref 27	Characterization of ABT-806, a Humanized Tumor-Specific Anti-EGFR Monoclonal Antibody. Mol Cancer Ther. 2015 May;14(5):1141-51. doi: 10.1158/1535-7163.MCT-14-0820. Epub 2015 Mar 2.
Ref 28	Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics. 2005 Aug;86(2):127-41. doi: 10.1016/j.ygeno.2005.04.008.
Ref 29	Phase I dose escalation study of ASP8273, a mutant-selective irreversible EGFR inhibitor, in subjects with EGFR mutation positive NSCLC, Journal of Clinical Oncology, Vol 33, No 15_suppl (May 20 Supplement), 2015: 8083.
Ref 30	Marine-Sourced Anti-Cancer and Cancer Pain Control Agents in Clinical and Late Preclinical Development. Mar Drugs. 2014 January; 12(1): 255-278.
Ref 31	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 32	Matuzumab binding to EGFR prevents the conformational rearrangement required for dimerization. Cancer Cell. 2008 Apr;13(4):365-73. doi: 10.1016/j.ccr.2008.02.019.
Ref 33	Active antimetastatic immunotherapy in Lewis lung carcinoma with self EGFR extracellular domain protein in VSSP adjuvant. Int J Cancer. 2006 Nov 1;119(9):2190-9.
Ref 34	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 35	Molecular mechanisms of resistance to the EGFR monoclonal antibody cetuximab. Cancer Biol Ther. 2011 May 1;11(9):777-92. doi: 10.4161/cbt.11.9.15050. Epub 2011 May 1.
Ref 36	Monoclonal antibodies to target epidermal growth factor receptor-positive tumors: a new paradigm for cancer therapy. Cancer. 2002 Mar 1;94(5):1593-611. doi: 10.1002/cncr.10372.
Ref 37	EGFR tyrosine kinase inhibitor pelitinib regulates radiation-induced p65-dependent telomerase activation in squamous cell carcinoma. Radiat Res. 2013 Mar;179(3):304-12. doi: 10.1667/RR3028.1. Epub 2013 Feb 4.
Ref 38	BiPar Sciences Co-founder Reunites Management Team At TriAct Therapeutics to Advance Clinical Stage Cancer Programs. TriAct Therapeutics. Sept. 10, 2009.
Ref 39	AC480, formerly BMS-599626, a pan Her inhibitor, enhances radiosensitivity and radioresponse of head and neck squamous cell carcinoma cells in vitro and in vivo. Invest New Drugs. 2011 Aug;29(4):554-61. doi: 10.1007/s10637-010-9389-3. Epub 2010 Feb 2.
Ref 40	Tarloxotinib Is a Hypoxia-Activated Pan-HER Kinase Inhibitor Active Against a Broad Range of HER-Family Oncogenes. Clin Cancer Res. 2021 Mar 1;27(5):1463-1475. doi: 10.1158/1078-0432.CCR-20-3555. Epub 2020 Dec 22.
Ref 41	Preclinical pharmacokinetics and in vitro metabolism of BMS-690514, a potent inhibitor of EGFR and VEGFR2. J Pharm Sci. 2010 Aug;99(8):3579-93. doi: 10.1002/jps.22099.
Ref 42	ClinicalTrials.gov (NCT01869166) Treatment of Chemotherapy Refractory EGFR(Epidermal Growth Factor Receptor) Positive Advanced Solid Tumors (CART-EGFR)
Ref 43	ClinicalTrials.gov (NCT03152435) EGFR CART Cells for Patients With Metastatic Colorectal Cancer
Ref 44	Regression of EGFR positive established solid tumors in mice with the conditionally active T cell engager TAK-186. J Immunother Cancer. 2022 Jun;10(6):e004336.
Ref 45	Clinical pipeline report, company report or official report of Zentalis Pharmaceuticals.
Ref 46	Clinical pipeline report, company report or official report of EpimAb Biotherapeutics.
Ref 47	Clinical pipeline report, company report or official report of Black Diamond Therapeutics.
Ref 48	Clinical pipeline report, company report or official report of Affimed Therapeutics.
Ref 49	Clinical pipeline report, company report or official report of Shionogi (2011).
Ref 50	Phase I and pharmacokinetic study of BIBX 1382 BS, an epidermal growth factor receptor (EGFR) inhibitor, given in a continuous daily oral administration. Eur J Cancer. 2002 May;38(8):1072-80. doi: 10.1016/s0959-8049(02)00020-5.
Ref 51	World Antibody-Drug Conjugate Summit, October 15-16, 2013, San Francisco, CA. MAbs. 2014 January 1; 6(1): 18-29.
Ref 52	AST1306, a novel irreversible inhibitor of the epidermal growth factor receptor 1 and 2, exhibits antitumor activity both in vitro and in vivo. PLoS One. 2011;6(7):e21487. doi: 10.1371/journal.pone.0021487. Epub 2011 Jul 18.
Ref 53	AMG 595, an Anti-EGFRvIII Antibody-Drug Conjugate, Induces Potent Antitumor Activity against EGFRvIII-Expressing Glioblastoma. Mol Cancer Ther. 2015 Jul;14(7):1614-24. doi: 10.1158/1535-7163.MCT-14-1078. Epub 2015 Apr 30.
Ref 54	ClinicalTrials.gov (NCT03638167) EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors
Ref 55	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
Ref 56	A Phase I Study of Immunotoxin, MR1-1. Duke University report.
Ref 57	ClinicalTrials.gov (NCT02331693) CAR T Cells in Treating Patients With Malignant Gliomas Overexpressing EGFR
Ref 58	TAS6417, A Novel EGFR Inhibitor Targeting Exon 20 Insertion Mutations. Mol Cancer Ther. 2018 Aug;17(8):1648-1658. doi: 10.1158/1535-7163.MCT-17-1206. Epub 2018 May 10.
Ref 59	Bispecific antibodies rise again. Nat Rev Drug Discov. 2014 Nov;13(11):799-801. doi: 10.1038/nrd4478.
Ref 60	Company report (Biooncology)
Ref 61	ClinicalTrials.gov (NCT04429542) Study of Safety and Tolerability of BCA101 Alone and in Combination With Pembrolizumab in Patients With EGFR-driven Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 62	A Phase I Study of CUDC-101, a Multitarget Inhibitor of HDACs, EGFR, and HER2, in Combination with Chemoradiation in Patients with Head and Neck Squamous Cell Carcinoma. Clin Cancer Res. 2015 Apr 1;21(7):1566-73. doi: 10.1158/1078-0432.CCR-14-2820. Epub 2015 Jan 8.
Ref 63	Clinical pipeline report, company report or official report of SystImmune.
Ref 64	Clinical pipeline report, company report or official report of CytomX
Ref 65	Clinical pipeline report, company report or official report of AstraZeneca
Ref 66	Improved efficacy against malignant brain tumors with EGFRwt/EGFRvIII targeting immunotoxin and checkpoint inhibitor combinations. J Immunother Cancer. 2019 May 29;7(1):142. doi: 10.1186/s40425-019-0614-0.
Ref 67	Clinical pipeline report, company report or official report of Merus.
Ref 68	National Cancer Institute Drug Dictionary (drug id 596693).
Ref 69	Pyrrolo[2,3-d]pyrimidines active as Btk inhibitors. Expert Opin Ther Pat. 2017 Dec;27(12):1305-1318. doi: 10.1080/13543776.2017.1355908. Epub 2017 Jul 20.
Ref 70	Epidermal growth factor receptor inhibitor PKI-166 governs cardiovascular protection without beneficial effects on the kidney in hypertensive 5/6 nephrectomized rats. J Pharmacol Exp Ther. 2013 Jun;345(3):393-403. doi: 10.1124/jpet.113.203497. Epub 2013 Mar 25.
Ref 71	GA201 (RG7160): a novel, humanized, glycoengineered anti-EGFR antibody with enhanced ADCC and superior in vivo efficacy compared with cetuximab. Clin Cancer Res. 2013 Mar 1;19(5):1126-38. doi: 10.1158/1078-0432.CCR-12-0989. Epub 2012 Dec 3.
Ref 72	EGFR tyrosine kinase inhibitor (PD153035) improves glucose tolerance and insulin action in high-fat diet-fed mice. Diabetes. 2009 Dec;58(12):2910-9. doi: 10.2337/db08-0506. Epub 2009 Aug 20.
Ref 73	Clinical pipeline report, company report or official report of AstraZeneca (2009).
Ref 74	A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer. J Nucl Med. 2000 May;41(5):903-11.
Ref 75	Clinical pipeline report, company report or official report of Bristol-Myers Squibb.
Ref 76	The heparin-binding domain of heparin-binding EGF-like growth factor can target Pseudomonas exotoxin to kill cells exclusively through heparan sulfate proteoglycans. J Cell Sci. 1994 Sep;107 ( Pt 9):2599-608. doi: 10.1242/jcs.107.9.2599.
Ref 77	Retinoic acid-induced RB (retinoblastoma) hypophosphorylation enhanced by CGP 52411 (4,5-dianilinophthalimide), an EGF family tyrosine kinase receptor inhibitor. Eur J Cell Biol. 1996 Apr;69(4):327-34.
Ref 78	Dianilinophthalimides: potent and selective, ATP-competitive inhibitors of the EGF-receptor protein tyrosine kinase. J Med Chem. 1994 Apr 1;37(7):1015-27.
Ref 79	WO patent application no. 2009,0582,67, Benzomorpholine derivatives and methods of use.
Ref 80	Novel nitrogen mustard-armed combi-molecules for the selective targeting of epidermal growth factor receptor overexperessing solid tumors: discovery of an unusual structure-activity relationship. J Med Chem. 2007 May 31;50(11):2605-8. doi: 10.1021/jm070144p. Epub 2007 May 2.
Ref 81	Protein-tyrosine kinase inhibition: mechanism-based discovery of antitumor agents. J Nat Prod. 1992 Nov;55(11):1529-60. doi: 10.1021/np50089a001.
Ref 82	Synthesis and inhibitory activity of 4-alkynyl and 4-alkenylquinazolines: identification of new scaffolds for potent EGFR tyrosine kinase inhibitors. Bioorg Med Chem Lett. 2007 Nov 1;17(21):5863-7. doi: 10.1016/j.bmcl.2007.08.020. Epub 2007 Aug 15.
Ref 83	Tyrosine kinase inhibitors. 5. Synthesis and structure-activity relationships for 4-[(phenylmethyl)amino]- and 4-(phenylamino)quinazolines as potent adenosine 5'-triphosphate binding site inhibitors of the tyrosine kinase domain of the epidermal growth factor receptor. J Med Chem. 1995 Sep 1;38(18):3482-7. doi: 10.1021/jm00018a008.
Ref 84	Growth factors and their receptors: new targets for prostate cancer therapy. Urology. 2001 Aug;58(2 Suppl 1):114-22. doi: 10.1016/s0090-4295(01)01253-5.
Ref 85	Tyrphostins I: synthesis and biological activity of protein tyrosine kinase inhibitors. J Med Chem. 1989 Oct;32(10):2344-52. doi: 10.1021/jm00130a020.
Ref 86	Tyrphostins. 2. Heterocyclic and alpha-substituted benzylidenemalononitrile tyrphostins as potent inhibitors of EGF receptor and ErbB2/neu tyrosine kinases. J Med Chem. 1991 Jun;34(6):1896-907. doi: 10.1021/jm00110a022.
Ref 87	Tyrosine kinase inhibitors. 9. Synthesis and evaluation of fused tricyclic quinazoline analogues as ATP site inhibitors of the tyrosine kinase activity of the epidermal growth factor receptor. J Med Chem. 1996 Feb 16;39(4):918-28. doi: 10.1021/jm950692f.
Ref 88	Tyrosine kinase inhibitors. 10. Isomeric 4-[(3-bromophenyl)amino]pyrido[d]-pyrimidines are potent ATP binding site inhibitors of the tyrosine kinase function of the epidermal growth factor receptor. J Med Chem. 1996 Apr 26;39(9):1823-35. doi: 10.1021/jm9508651.
Ref 89	A systematic interaction map of validated kinase inhibitors with Ser/Thr kinases. Proc Natl Acad Sci U S A. 2007 Dec 18;104(51):20523-8. doi: 10.1073/pnas.0708800104. Epub 2007 Dec 11.
Ref 90	Acryloylamino-salicylanilides as EGFR PTK inhibitors. Bioorg Med Chem Lett. 2006 Jan 15;16(2):469-72. doi: 10.1016/j.bmcl.2005.06.088. Epub 2005 Nov 3.
Ref 91	Computational studies of epidermal growth factor receptor: docking reliability, three-dimensional quantitative structure-activity relationship analysis, and virtual screening studies. J Med Chem. 2009 Feb 26;52(4):964-75. doi: 10.1021/jm800829v.
Ref 92	Selected novel anticancer treatments targeting cell signaling proteins. Oncologist. 2001;6(6):517-37. doi: 10.1634/theoncologist.6-6-517.
Ref 93	5-Benzylidene-hydantoins: synthesis and antiproliferative activity on A549 lung cancer cell line. Eur J Med Chem. 2009 Sep;44(9):3471-9. doi: 10.1016/j.ejmech.2009.01.035. Epub 2009 Feb 7.
Ref 94	Tyrosine kinase inhibitors. 8. An unusually steep structure-activity relationship for analogues of 4-(3-bromoanilino)-6,7-dimethoxyquinazoline (PD 153035), a potent inhibitor of the epidermal growth factor receptor. J Med Chem. 1996 Jan 5;39(1):267-76. doi: 10.1021/jm9503613.
Ref 95	5,7-Dimethoxy-3-(4-pyridinyl)quinoline is a potent and selective inhibitor of human vascular beta-type platelet-derived growth factor receptor tyrosine kinase. J Med Chem. 1994 Aug 19;37(17):2627-9. doi: 10.1021/jm00043a002.
Ref 96	Use of a pharmacophore model for the design of EGFR tyrosine kinase inhibitors: isoflavones and 3-phenyl-4(1H)-quinolones. J Med Chem. 1999 Mar 25;42(6):1018-26. doi: 10.1021/jm980551o.
Ref 97	Tyrosine kinase inhibitors. 15. 4-(Phenylamino)quinazoline and 4-(phenylamino)pyrido[d]pyrimidine acrylamides as irreversible inhibitors of the ATP binding site of the epidermal growth factor receptor. J Med Chem. 1999 May 20;42(10):1803-15. doi: 10.1021/jm9806603.
Ref 98	Synthesis of a prodrug designed to release multiple inhibitors of the epidermal growth factor receptor tyrosine kinase and an alkylating agent: a novel tumor targeting concept. J Med Chem. 2003 Dec 4;46(25):5546-51. doi: 10.1021/jm030423m.
Ref 99	Syntheses of 4-(indole-3-yl)quinazolines: a new class of epidermal growth factor receptor tyrosine kinase inhibitors. Eur J Med Chem. 2008 Jul;43(7):1478-88. doi: 10.1016/j.ejmech.2007.09.018. Epub 2007 Sep 29.
Ref 100	Effects of hEGF (MG111) on gastric mucosal potential difference in rats. Scand J Gastroenterol Suppl. 1989;162:198-201. doi: 10.3109/00365528909091160.
Ref 101	The combi-targeting concept: synthesis of stable nitrosoureas designed to inhibit the epidermal growth factor receptor (EGFR). J Med Chem. 2006 Jun 15;49(12):3544-52. doi: 10.1021/jm0600390.
Ref 102	Cochliobolic acid, a novel metabolite produced by Cochliobolus lunatus, inhibits binding of TGF-alpha to the EGF receptor in a SPA assay. J Nat Prod. 1997 Jan;60(1):6-8. doi: 10.1021/np9605293.
Ref 103	Structure-guided development of affinity probes for tyrosine kinases using chemical genetics. Nat Chem Biol. 2007 Apr;3(4):229-38. doi: 10.1038/nchembio866. Epub 2007 Mar 4.
Ref 104	A novel series of 4-phenoxyquinolines: potent and highly selective inhibitors of PDGF receptor autophosphorylation, Bioorg. Med. Chem. Lett. 7(23):2935-2940 (1997).
Ref 105	Clinical pipeline report, company report or official report of Biocytogen
Ref 106	Novel antiproliferative agents derived from lavendustin A. J Med Chem. 1994 Nov 25;37(24):4079-84. doi: 10.1021/jm00050a005.
Ref 107	Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J Med Chem. 2005 Feb 24;48(4):1107-31. doi: 10.1021/jm040159c.
Ref 108	Discovery and SAR of 6-substituted-4-anilinoquinazolines as non-competitive antagonists of mGlu5. Bioorg Med Chem Lett. 2009 Dec 1;19(23):6623-6. doi: 10.1016/j.bmcl.2009.10.024. Epub 2009 Oct 9.
Ref 109	Anthraquinones and betaenone derivatives from the sponge-associated fungus Microsphaeropsis species: novel inhibitors of protein kinases. J Nat Prod. 2000 Jun;63(6):739-45. doi: 10.1021/np9905259.
Ref 110	Indazolylamino quinazolines and pyridopyrimidines as inhibitors of the EGFr and C-erbB-2. Bioorg Med Chem Lett. 2001 Jun 4;11(11):1401-5. doi: 10.1016/s0960-894x(01)00219-0.
Ref 111	Tyrosine kinase inhibitors. 19. 6-Alkynamides of 4-anilinoquinazolines and 4-anilinopyrido[3,4-d]pyrimidines as irreversible inhibitors of the erbB family of tyrosine kinase receptors. J Med Chem. 2006 Feb 23;49(4):1475-85. doi: 10.1021/jm050936o.
Ref 112	The specificity of JAK3 kinase inhibitors. Blood. 2008 Feb 15;111(4):2155-7. doi: 10.1182/blood-2007-09-115030. Epub 2007 Dec 19.
Ref 113	Discovery of a series of 2,5-diaminopyrimidine covalent irreversible inhibitors of Bruton's tyrosine kinase with in vivo antitumor activity. J Med Chem. 2014 Jun 26;57(12):5112-28. doi: 10.1021/jm4017762. Epub 2014 Jun 10.
Ref 114	Biochemical and cellular effects of c-Src kinase-selective pyrido[2, 3-d]pyrimidine tyrosine kinase inhibitors. Biochem Pharmacol. 2000 Oct 1;60(7):885-98. doi: 10.1016/s0006-2952(00)00405-6.
Ref 115	Targeted polypharmacology: discovery of dual inhibitors of tyrosine and phosphoinositide kinases. Nat Chem Biol. 2008 Nov;4(11):691-9. doi: 10.1038/nchembio.117. Epub 2008 Oct 12.
Ref 116	Design, synthesis, and biological evaluation of 3,4-diarylmaleimides as angiogenesis inhibitors. J Med Chem. 2006 Feb 23;49(4):1271-81. doi: 10.1021/jm0580297.
Ref 117	Biological evaluation of a multi-targeted small molecule inhibitor of tumor-induced angiogenesis. Bioorg Med Chem Lett. 2006 Apr 1;16(7):1950-3. doi: 10.1016/j.bmcl.2005.12.092. Epub 2006 Feb 3.
Ref 118	TTD: Therapeutic Target Database describing target druggability information. Nucleic Acids Res. 2024 Jan 5;52(D1):D1465-D1477. doi: 10.1093/nar/gkad751.
Ref 119	FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 216340.
Ref 120	FDA Approved Drug Products from FDA Official Website. 2022. Application Number: 761210.
Ref 121	ClinicalTrials.gov (NCT04129502) TAK-788 as First-line Treatment Versus Platinum-Based Chemotherapy for Non-Small Cell Lung Cancer (NSCLC) With EGFR Exon 20 Insertion Mutations. U.S. National Institutes of Health.
Ref 122	Sugemalimab: First Approval. Drugs. 2022 Apr;82(5):593-599.
Ref 123	ClinicalTrials.gov (NCT05089734) Open-Label, Global, Multicenter, Randomized, Phase 3 Study of Sacituzumab Govitecan Versus Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) With Progression on or After Platinum-Based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy. U.S.National Institutes of Health.
Ref 124	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
Ref 125	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2021
Ref 126	FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 214665.
Ref 127	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2019
Ref 128	FDA Approved Drug Products from FDA Official Website. 2023. Application Number: 218213
Ref 129	ClinicalTrials.gov (NCT04633564) Multicenter, Double-Blind, Randomized, Parallel-Group Study to Assess the Efficacy and Safety of MYL-1402O Compared With Avastin?, in the First-line Treatment of Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer. U.S.National Institutes of Health.
Ref 130	ClinicalTrials.gov (NCT04736173) Study to Evaluate Monotherapy Compared to Combination Immunotherapies in Participants With PD-L1 Positive Non-small Cell Lung Cancer. U.S. National Institutes of Health.
Ref 131	ClinicalTrials.gov (NCT05555732) A Randomized Phase 3 Study of Datopotamab Deruxtecan (Dato-DXd) and Pembrolizumab With or Without Platinum Chemotherapy in Subjects With No Prior Therapy for Advanced or Metastatic PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung07). U.S.National Institutes of Health.
Ref 132	ClinicalTrials.gov (NCT03728556) A Study of CS1001 in Subjects With Stage III Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
Ref 133	ClinicalTrials.gov (NCT05132075) A Randomized, Controlled, Open Label, Phase III Study Evaluating the Efficacy and Safety of JDQ443 Versus Docetaxel in Previously Treated Subjects With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer. U.S.National Institutes of Health.
Ref 134	ClinicalTrials.gov (NCT04416035) A Phase 3, Multicenter, Randomized and Double-Blind Study to Assess the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab in Subjects With Advanced Nonsquamous NSCLC. U.S.National Institutes of Health.
Ref 135	ClinicalTrials.gov (NCT05245071) Open-label, Phase 2 Study, Evaluating the Efficacy and Safety of Tusamitamab Ravtansine in Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC) Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA. U.S.National Institutes of Health.
Ref 136	ClinicalTrials.gov (NCT04294810) A Study of Tiragolumab in Combination With Atezolizumab Compared With Placebo in Combination With Atezolizumab in Patients With Previously Untreated Locally Advanced Unresectable or Metastatic PD-L1-Selected Non-Small Cell Lung Cancer (SKYSCRAPER-01). U.S. National Institutes of Health.
Ref 137	ClinicalTrials.gov (NCT04655976) Study of Cobolimab in Combination With Dostarlimab and Docetaxel in Advanced NSCLC Participants (COSTAR Lung). U.S. National Institutes of Health.
Ref 138	ClinicalTrials.gov (NCT04258033) A Study of PLB1001 in Non-small Cell Lung Cancer With c-Met Dysregulation. U.S. National Institutes of Health.
Ref 139	ClinicalTrials.gov (NCT04032704) A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 140	ClinicalTrials.gov (NCT05557591) A Phase 2 Study of Cemiplimab (Anti-PD-1 Antibody) in Combination With BNT116 (FixVac Lung) Versus Cemiplimab Monotherapy in First-Line Treatment of Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) With Tumors Expressing PD-L1 >=50%. U.S.National Institutes of Health.
Ref 141	ClinicalTrials.gov (NCT04931654) A Phase I/IIa Open-label Dose Escalation and Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD7789, an Anti-PD-1 and Anti-TIM-3 Bispecific Antibody, in Participants With Advanced or Metastatic Solid Tumors. U.S.National Institutes of Health.
Ref 142	ClinicalTrials.gov (NCT02340208) A Phase I/II Open-Label, Non-Randomized Dose Escalation Study of Immunoconjugate L-DOS47. U.S. National Institutes of Health.
Ref 143	ClinicalTrials.gov (NCT04699123) The Study of NC318 Alone or in Combination With Pembrolizumab in Patients With Advanced Non-small Cell Lung Cancer. U.S. National Institutes of Health.
Ref 144	ClinicalTrials.gov (NCT03848611) CM082 and JS001 in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC).. U.S. National Institutes of Health.
Ref 145	ClinicalTrials.gov (NCT02283749) BrUOG L301: Xofigo Following Frontline-Line Chemotherapy For Patients With Non-Small Cell Lung Cancer and Bone Metastases. U.S.National Institutes of Health.
Ref 146	ClinicalTrials.gov (NCT04560686) Bintrafusp Alfa Before Surgery for the Treatment of Untreated Resectable Non-small Cell Lung Cancer. U.S. National Institutes of Health.
Ref 147	ClinicalTrials.gov (NCT04291105) Phase 2 Trial of Voyager V1 in Combination With Cemiplimab in Cancer Patients. U.S. National Institutes of Health.
Ref 148	ClinicalTrials.gov (NCT04395677) A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene. U.S. National Institutes of Health.
Ref 149	ClinicalTrials.gov (NCT04625270) A Study of VS-6766 v. VS-6766 + Defactinib in Recurrent Low-Grade Serous Ovarian Cancer With and Without a KRAS Mutation. U.S. National Institutes of Health.
Ref 150	ClinicalTrials.gov (NCT03907852) Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer. U.S. National Institutes of Health.
Ref 151	ClinicalTrials.gov (NCT03797391) A Dose Escalation Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors. U.S. National Institutes of Health.
Ref 152	ClinicalTrials.gov (NCT04442126) A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 153	ClinicalTrials.gov (NCT03637803) Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors. U.S. National Institutes of Health.
Ref 154	ClinicalTrials.gov (NCT03974022) Assessing an Oral EGFR Inhibitor, DZD9008 in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1). U.S. National Institutes of Health.
Ref 155	ClinicalTrials.gov (NCT03744468) Study of BGB-A425 in Combination With Tislelizumab in Advanced Solid Tumors. U.S. National Institutes of Health.
Ref 156	ClinicalTrials.gov (NCT04995523) Phase I/II, Open-label, Dose Escalation and Dose Expansion Study to Evaluate Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC. U.S.National Institutes of Health.
Ref 157	ClinicalTrials.gov (NCT03696212) Open Label, Single Arm, Phase 1b/2 Study to Evaluate the Safety and Efficacy of Grapiprant (ARY-007) in Combination With Pembrolizumab in Patients With Advanced or Metastatic Post-PD-1/L1 Non-Small Cell Lung Cancer (NSCLC) Adenocarcinoma. U.S.National Institutes of Health.
Ref 158	ClinicalTrials.gov (NCT04777084) The Efficacy and Safety of the Bispecific Anti-PD-1/PD-L1 Antibody IBI318 Combined With Lenvatinib in NSCLC.. U.S. National Institutes of Health.
Ref 159	ClinicalTrials.gov (NCT04596033) TiTAN-1: Safety, Proliferation and Persistence of GEN-011 Autologous Cell Therapy. U.S. National Institutes of Health.
Ref 160	ClinicalTrials.gov (NCT05401110) IIT2021-12-Reckamp-Osi105: Phase I Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer. U.S.National Institutes of Health.
Ref 161	ClinicalTrials.gov (NCT04822298) Study of AMG 160 in Subjects With Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
Ref 162	Phase I clinical trial evaluating the safety and efficacy of ADP-A2M10 SPEAR T cells in patients with MAGE-A10(+) advanced non-small cell lung cancer. J Immunother Cancer. 2022 Jan;10(1):e003581.
Ref 163	ClinicalTrials.gov (NCT03819465) A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN). U.S. National Institutes of Health.
Ref 164	ClinicalTrials.gov (NCT04553133) PF-07104091 as a Single Agent and in Combination Therapy. U.S. National Institutes of Health.
Ref 165	ClinicalTrials.gov (NCT03674827) Vaccine-Based Immunotherapy Regimen For NSCLC and TNBC. U.S. National Institutes of Health.
Ref 166	ClinicalTrials.gov (NCT03927573) Study With Bispecific Antibody Engaging T-cells, in Patients With Progressive Cancer Diseases With Positive PSCA Marker. U.S. National Institutes of Health.
Ref 167	ClinicalTrials.gov (NCT04881045) A PHASE 1 DOSE ESCALATION AND EXPANSION STUDY EVALUATING THE SAFETY, TOLERABILITY, PHARMACOKINETICS, PHARMACODYNAMICS, AND ANTITUMOR ACTIVITY OF PF-07257876 IN PATIENTS WITH ADVANCED OR METASTATIC TUMORS. U.S.National Institutes of Health.
Ref 168	ClinicalTrials.gov (NCT04786964) Study of Pemetrexed+Platinum Chemotherapy With or Without Cosibelimab (CK-301) in First Line Metastatic Non-squamous Non-Small Cell Lung Cancer (CONTERNO). U.S. National Institutes of Health.
Ref 169	Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 170	Pim-1 inhibitor SMI-4a suppresses tumor growth in non-small cell lung cancer via PI3K/AKT/mTOR pathway. Onco Targets Ther. 2019 Apr 23;12:3043-3050.

m6A-centered Crosstalk Information

Cite M6AREG

Correspondence

Prof. Feng ZHU

Prof. Shuiping Liu

Visitor Map